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Abstract

THE EFFECT OF ANTICHOLINERGIC BURDEN ON FUNCTIONAL OUTCOMES IN
PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE

By: Sheetal Prabodh Dharia

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Dr. Patricia W. Slattum, Pharm.D./Ph.D.
Associate Professor and Geriatric Pharmacotherapy Program Director
Department of Pharmacotherapy and Outcomes Science

Background: Alzheimer’s disease (AD) is the most common form of dementia and is
characterized by a progressive loss of memory, judgment, and thinking in older adults. The
current treatment is cholinesterase inhibitors, which increase acetylcholine at the synapse.
Medications with anticholinergic (AC) activity are given for a variety reasons including for the
treatment of comorbid conditions or side effects of cholinesterase inhibitors (ChEIs).

xi

These drugs inhibit acetylcholine in the brain. Studies have shown the detrimental outcomes of
using AC medications with ChEIs in older adults. Moreover, older patients take more
medications and have an increased risk of developing AC toxicity as these effects are additive.
The association between AC burden with functional, cognitive, and behavioral outcomes bears
further evaluation.
Methods: This study is a retrospective observational study that investigated the effect of AC
medications on function, cognition, and behavior. Data was collected from charts on dementia
patients who resided at Piedmont Geriatric Hospital. Descriptive statistics and GEE regression
were performed using MS Excel 2007 and SPSS 18.0.
Results: There were a total of 83 subjects included in this study with a median age of 77 years
old and with a median length of stay of 536 days. 33.7% of the patients were taking cognitiveenhancing medications. The analysis found that AC burden was not a significant predictor of
functional, cognitive or behavioral decline.
Conclusion: The minimal amount of literature on this association, suggests that AC burden may
have negative consequences on function, cognition and behavior in dementia patients. The study
results provided inconclusive evidence about the association of AC burden on poorer functional,
cognitive and behavioral outcomes. Future research in this field is needed to determine if there
is a true association between worsening outcomes and AC burden.

xii

Chapter 1
Introduction
1.0 Chapter Introduction
This diversified chapter introduces Alzheimer’s disease, anticholinergic drugs and burden as well
as the barriers to research. Dementia, especially Alzheimer’s disease (AD), is a chronic disease
that lacks a cure. Cholinesterase inhibitors (ChEIs) are a symptomatic treatment for AD. Other
drugs with anticholinergic properties are typically used as treatment for comorbid conditions
associated with AD. This second class of drugs, anticholinergic (AC) medications, has been
associated with negative outcomes in older adults. There is some evidence and suggestion that
these AC medications may be associated with negative outcomes in dementia patients as well,
but the link between dementia and negative effects as a result of anticholinergic properties is not
well defined due in part to barriers to conducting research in patients with dementia. One
potential reason for this lack of evidence is difficulty in recruiting older dementia patients to
participate in studies.
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia in older adults, accounting for 60 to
80% of all dementia cases.
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The Alzheimer’s Association estimates that currently over 5.3 million Americans suffer from
AD and that by 2050 an estimated 11 to 16 million people over the age of 65 will be affected
(Alzheimer’s Association, 2010).
AD is a progressive neurodegenerative disorder that has particular clinical and pathological
changes associated with it.

The disease damages the limbic structures, specifically the

hippocampus, cholinergic system and neocortical pathways (Maccioni et al, 2009). Clinically
this is characterized by a progressive loss of memory, judgment, and thinking in the older
population. This disease affects each individual differently. The most common pattern of
progression starts with difficulty remembering new information possibly followed by memory
loss, loss of executive functioning, difficulty in completing familiar tasks, confusion with spatial
information, problems with language and perception, withdrawal from social activities, and
changes in personality (Alzheimer’s Association, 2010). It is suggested that the symptomatic
course is generally 5 to 10 or more years from the time that the memory deficits appear. Other
evidence suggests that a seven year pre-clinical decline occurs (Shah et al, 2008).
The mechanism of neurodegeneration is not well understood, but it is suggested that the
neurodegenerative process starts with damage to the synaptic terminals that leads to eventual
neuronal loss (Maccioni et al, 2009). Loss of the synapse occurs and is correlated with cognitive
decline. This damage is caused by the formation and proliferation of plaques consisting of
amyloid β (Aβ) peptides and neurofibrillary tangles composed of tau proteins (Maccioni et al,
2009).
The disease does not have a definitive cause and several theories have been developed to attempt
to understand and explain the basis of Alzheimer’s disease. The most widely held theory is the
2

Amyloid hypothesis in which AD is caused by the formation of plaques made by the deposition
of beta-amyloid peptides (Aβ) in brain tissue. These plaques are misfolded from the natural
occurring amyloid peptides. In addition, it is suggested that the formation of neurofibrillary
tangles by tau proteins is a result of the imbalance of Aβ production and clearance (Hardy et al,
2002). The amyloid hypothesis is compelling because the gene for the amyloid beta precursor
APP is located on chromosome 21. The regions linked to one type of familial AD are also on
chromosome 21.

Furthermore, Down syndrome patients who have an extra copy of this

chromosome present with disorders similar to AD by the age of 40.

Moreover, research has

found that there are genetic defects in the genes that code for APP in some types of familial AD.
In addition, genetic defects are also found in certain proteins, presenilin 1 and 2 which produce
the enzyme that produces one form of Aβ. It has been shown that mutations in presenilin 1 & 2
increase the levels of Aβ (Ropper et al, 2005).
One of the oldest hypotheses is the cholinergic hypothesis in which AD symptoms are caused by
a deficiency in the production of acetylcholine. This was based on the work of Whitehouse et al
in 1982, who found a selective loss of basal forebrain neurons in AD patients (Shah et al, 2008).
These neurons are the major source of cholinergic innervations in the cerebral cortex.
Cholinergic innervations of the brain extend to the cortical and hippocampal regions. These
regions are important to the processes of memory, language, and visuospatial skills. Cholinergic
neurons develop from the nucleus basalis of Meynert to both the hippocampus and the cortex.
Transmissions through these innervations are very important in normal cognitive functioning
(Kay et al, 2005A). The degeneration of the cholinergic circuits and impaired cholinergic
transmission has been associated with cognitive dysfunction. Therefore, the first-generation antiAlzheimer's medications are based on this hypothesis and work to preserve acetylcholine
3

activity.

This class of drugs reversibly inhibits the enzyme acetylcholinesterase, which is

responsible for the breakdown of acetylcholine at the synapse into choline and acetate. The
inhibition of this enzyme prolongs the activity of the existing acetylcholine at the synapse
thereby perpetuating the signal longer. There is some evidence that these drugs may stabilize the
disease for a short period of time, but there is no evidence of disease modification (Shah et al,
2008). The proposed mechanism of stabilization is based on the β-amyloid-cholinesterase-cyclooxygenase-2 cycle. The idea is that β-amyloid increases the expression of both AChE and cyclooxygenase 2 (COX-2) in the brain. The inhibition of AChE by ChEIs increases the release of
APP and reduces β-amyloid deposits as well as COX-2 expression, which is suggested to cause
inflammation in AD (Giacobini, 2001). This class of medications, acetylcholinesterase inhibitors
(AChEI), contains four drugs that are still on the market. The first is tacrine that is rarely used as
it requires dosing four times per day and has been linked to hepatotoxicity. The other three drugs
include donepezil, galantamine and rivastigmine. These drugs have greater efficacy compared to
tacrine. The most commonly prescribed AChEI is donepezil, which has indications for mild
through severe disease. The other AChEIs have an FDA approved indication only for mild and
moderate disease.
There is a second class of drugs that is used for the treatment of AD. This class, N-methyl-Daspartate (NMDA) receptor antagonists are used based on the premise that the release of
glutamate in the CNS may play a role in excitotoxic reactions thereby leading to cell death
(Koda-Kimble et al, 2005). Memantine, an uncompetitive antagonist that works by blocking
glutamatergic neurotransmission by antagonizing this receptor, is the only medication of this
class currently on the market in the US. It has an indication for monotherapy in moderate to
4

severe disease and studies suggest when combined with AChEIs there is more improvement in
cognition and ADLs than with memantine alone.
A review of the clinical trial data by a Cochrane review in 2006, found that after treatment for 6
months with the three AChEIs, there were some improvements in cognitive functioning,
behavior and function. The positive improvements were mild or small with a 2-3 point decrease
on the ADAS-Cog (Birks, 2006), the gold-standard in measurement of cognitive functioning in
AD trials. These mild improvements on assessments do not translate to significant clinical
improvements. Furthermore, adverse events were not uncommon.

There was a significant

difference in the percentage of treatment patients, 29%, who withdrew due to adverse events
compared to the placebo group, 18%. There were forty-seven types of adverse events that
occurred among the several AChEI trials.

The most commonly reported events include

abdominal pain, anorexia, abnormal dreams, asthenia, diarrhea, dizziness, fatigue, headache,
insomnia, muscle cramp, nausea, syncope, tremor, peripheral edema, vertigo, weight loss and
vomiting. These adverse events occurred significantly more in treatment patients than in placebo
(Birks, 2006). Moreover, in a study by Gill et al it was found that as many as 51% to 78% of the
older adults assessed would not have been eligible to participate in the ChEI clinical trials.
Additionally, they found that their cohort was older and more likely to be living in long-term
care compared to the clinical trial participants (Gill et al, 2004). Finally, cost-effectiveness
studies that have been completed have shown that these medications may not be cost-effective.
Also, the cost-savings associated with reducing the time spent in full-time care does not balance
the cost of the treatment (Loveman et al, 2006).

5

1.2 Anticholinergic Medications:
1.2.1 Definition and Exposure
Anticholinergic (AC) medications play an important role in patients with Alzheimer’s disease as
they are frequently added to medication regimens to treat comorbid conditions. These drugs, as
the name would suggest, antagonize cholinergic receptors. There are two types of cholinergic
receptors, muscarinic and nicotinic. There are five subtypes of muscarinic receptors M1-M5;
three of which are important in cognitive functioning (Katzum BG, 2001). These include M1,
M2 and M4, which are located CNS. All of the muscarinic receptor subtypes are distributed
throughout the brain. The M1 subtype is most abundant in the CNS, especially the hippocampus,
neocortex, and the neostriatum. The M2 receptor is located throughout the brain and the M4
specifically in the neostriatum. The M5 are localized to the hippocampus with projections in the
substantia nigra, pars compacta and ventral tegmental nuclei. The M3 subtype is the only one
that has low levels in the brain. Pharmacological studies that investigated the role of these
receptors found that in M1 knockout mice there are impairments in spatial memory and severe
deficits in working memory.

In M2 knockout mice, impaired behavioral tasks requiring

working memory and impaired regulation in cholinergic functioning was seen. Furthermore,
studies have shown that blockade of M1 and M2 receptors is associated with increased amyloid
plaques and neurofibrillary tangles compared to normal controls (Kay et al, 2005A; Perry et al,
2003). Other studies have linked M4 receptors to regulation of acetylcholine levels. Moreover,
these three subtypes may be involved in mediating cholinergic effects on motor and sensory
processes (Kay et al, 2005A). Additionally, one study suggested that antimuscarinic activity
may increase amyloid plaques. This is based on evidence that activation of M2 receptors
6

increases the amyloidogenic activity of two important secretases that are known to cleave APP
into a more aggregative form of amyloid. A study in Parkinson’s disease patients found that
chronic use of antimuscarinics was associated with higher rates of plaque and tangle formation
(Perry et al, 2003).
The aging process leads to a cholinergic deficit that may explain some of the increased
sensitivity to medications that block muscarinic receptors. There is some evidence that there are
age-related declines in M1 receptors. One study found that the density of the M1 receptor
subtype was 50% lower in an 82 year-old compared to a 19 year-old (Kay et al, 2005A).

In

addition, age-related physiologic changes affecting drug absorption, distribution, metabolism and
elimination processes may alter responses to drugs compared to younger counterparts.
Specifically, muscle metabolism is decreased and leads to increased fat deposition (Han et al,
2008), which affects the distribution of drugs in the body. In terms of drug metabolism, one
study suggests that in older adults over 70, there may be as much as a 30% decrease in
metabolism (Sotaniemi et al, 1997). Elimination processes are altered with age, chronic disease
and certain medications. Hepatic clearance is more likely to be prolonged with age, specifically
in drugs that undergo phase 1 metabolism. Those that undergo phase 2 only, are not typically
affected. In renal elimination, it is estimated that creatinine clearance decreases at an average 8
ml/min/decade after the age of 30 (Ruscin, 2009). This change decreases renal elimination of
some medications. Therefore there is an increased exposure to a drug and its metabolites in an
older adult. Furthermore, there is decreased functioning of cholinergic brain receptors and
increased permeability to the blood brain barrier (BBB) (Han et al, 2008).

In younger

counterparts, the BBB is made up of endothelial cells with tight junctions, which only allow
small, unpolarized, lipid-soluble molecules to pass through. As a person ages, these cells begin
7

to shrink and the tight junctions allow for the creation of channels which allow larger, more
polarized molecules into the brain. Other factors such as stress, comorbid diseases and some
medications may increase the permeability of the BBB.
There are several medications with AC properties and this is shown in Table 1, which is
compiled from the literature (Zarowitz et al, 2007; Ness et al, 2006; Lechevallier-Michael N
et al, 2004).
Table 1: Sample list of medications with AC properties

Generic Name
Antihistamines
Chlorpheniramine
Dexchlorpheniramine
Diphenhydramine
Hydroxyzine
Promethazine
Fexofenadine
Meclizine
Loratadine
Doxylamine
Antimuscarinics
Oxybutynin
Tolterodine
Darifenacin
Solifenacin
Trospium
Cardiovascular
Captopril
Digoxin
Diltiazem
Dipyridamole

Brand Name
Chlor-Trimeton
Polaramine
Benadryl
Vistaril/Atarax
Phenergan
Allegra
Antivert
Claritin
Unisom
Ditropan
Detrol
Enablex
Vesicare
Sanctura
Capoten
Lanoxin
Cardizem
Norpace

Generic Name
Benzodiazepines
Alprazolam
Chlordiazepoxide
Diazepam
Flurazepam
Oxazepam
Corticosteroids
Dexamethasone
Hydrocortisone
Prednisolone
Gastrointestinal
Atropine
Belladonna Alkaloids
Cimetidine
Clindiniumchlordiazepoxide
Dicyclomine
Hyoscyamine
Metoclopramide
Rantidine
Immunosuppression
Azathioprine
8

Brand Name
Xanax
Librium
Valium
Dalmane
Serax
Decadron
Cortef
Orapred

Donnatal
Tagamet
Librax
Bentyl
Levsin/Levsinex
Reglan
Zantac
Imuran

Generic Name
Furosemide
Hydrochlorothiazide
Isosorbide
mononitrate
Nifedipine
Triamterene
Warfarin
Anticonvulsants
Phenobarbital
Antidepressants
Amitriptyline
Desipramine
Doxepin
Imipramine
Mirtazipine
Nortriptyline
Trazodone
Paroxetine
Phenelzine
Antipsychotics
Clozapine
Olanzapine
Thioridazine
Narcotic Analgesics
Codeine
Oxycodone
Hydrocodone

Brand Name
Lasix
Microzide

Generic Name
Cyclosporin
Antibiotic

Imdur
Adalat/Procardia
Dyrenium
Coumadin

Ampicillin
Cefoxitin
Clindamycin
Cycloserine
Gatifloxacin
Gentamicin
Moxifloxacin

Elavil
Norpramin
Sinequan
Tofranil
Remeron
Aventyl/Pamelor
Desyrel
Paxil
Nardil

Piperacillin/Tazobactam
Tobramycin
Vancomycin
Muscle Relaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Metaxalone
Methocarbamol
Parkinson’s Disease
Amantadine
Benztropine
Trihexyphenidyl
Methyldopa
Respiratory

Clozaril
Zyprexa
Mellaril

OxyContin,
Percodan
Vicodin

Theophylline

Brand Name
Neoral/Sandimmune

Mefoxin
Cleocin
Seromycin
Tequin
Garamycin
Avelox
Zosyn
Nebcin
Vancocin
Soma
Paraflex
Flexeril
Skelaxin
Robaxin
Symmetrel
Cogentin
Artane
Aldomet
Theo24/Uniphyl/Theolair

As shown there are several medications, including warfarin and antibiotics, that one would not
typically consider as having AC properties. While relatively comprehensive, this list is only a
sample as many medications are not included including newer ones such as fesoterodine.
9

1.2.1.2 Anticholinergic Burden
The term anticholinergic burden (AC burden) refers to the cumulative effect of taking multiple
medications that block muscarinic receptors in the cholinergic nervous system. As discussed in
the previous section, AC medications are believed to be hazardous to older adults, especially
those with dementia. There is an additional issue of the cumulative effects of these medications.
The concern of AC toxicity resulting from cumulative AC burden of multiple medications is a
real issue for older adults (Kay et al, 2005A). The evidence in the literature provides some
insight as to the seriousness of AC burden. Han et al found that AC burden was significantly
associated with poor performance on memory and executive tasks, specifically the Hopkins
Verbal Recall Test (HVRT) and the Instrumental Activities of Daily Living (IADL) (Han et al,
2008). A study by Ancelin et al showed that continuous use of AC medications for greater than
one year was independently associated with poorer performance on attention, short-term memory
and visuospatial construction (Ancelin et al, 2006). Burden is not an issue relating to only longterm use of medications with AC properties. Short-term studies show that the cumulative burden
effects in older adults taking AC drugs for at least two weeks was associated with declines in
visual memory, verbal fluency, global cognitive function, and on activities of daily living scales
(Han et al, 2008). Recent studies have found that the cumulative effect of AC medications is
strongly associated with falls in hospitalized older adults (Nebes et al, 2007). The literature
suggests that older adults in the community are also at risk as many medications that are most
commonly prescribed have antimuscarinic properties (Lechevallier-Michael et al, 2004). Also,
many older adults use over the counter drugs with AC effects (Nebes et al, 2007).
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1.2.1.3 Factors Influencing AC Burden
There are many factors that can influence AC burden including pharmacokinetic and
pharmacodynamic changes, polypharmacy with medications that have AC properties, drug
interactions, comorbid disease states, especially dementia, specific drug exposure and the
integrity of the blood brain barrier.

Polypharmacy or the use of multiple medications is a

common problem in the older adult population. As mentioned earlier, older adults have an
increased sensitivity to AC adverse effects and the possibility of additional AC medications may
augment the consequences.

In many situations, older adults see multiple physicians who

prescribe multiple medications and to compound the problem they may not always go to the
same pharmacy to get the prescriptions filled. Furthermore, the older adults may not tell their
doctors about the other medications that they have been prescribed by another physician. This
situation has the potential to lead to serious drug interactions and anticholinergic toxicity. The
most common AC medications that older adults may forget to inform their healthcare
professionals include antidepressants and first generation antihistamines (Kay et al, 2005B).
First generation antihistamines include over-the-counter medications such as diphenhydramine,
chlorpheniramine and promethazine that are commonly found in allergy, cold/flu, sleep and
“PM” pain medications. Cognitive impairment is an important factor in determining the extent
of AC burden and also increases the risk of receiving an AC medication (Lechevallier-Michael et
al, 2004).
1.2.1.4 Determination of Anticholinergic Burden
Determination of AC activity has been around for several decades due to the numerous pesticides
and chemical weapons that irreversibly inhibit acetylcholinesterase, thereby resulting in the
11

depletion of acetylcholine. Techniques for assessing AC activity are summarized in Table 2.
Serum Anticholinergic Activity (SAA) radioreceptor assay is the laboratory assay that is the gold
standard for measuring anticholinergic burden. This method is currently the most direct method
of cumulative anticholinergic measurement, but is not practical in the clinical arena (Kolanowski
et al, 2009). In this assay, AC medications and metabolites in serum are added to rat brain
homogenate and competitively inhibit the binding of radiolabelled 3H- quinnuclidinyl benzilate
(3H-QNB), a cholinergic agonist. 3H-QNB binds with high affinity to all of the muscarinic
receptor subtypes. The amount of 3H-QNB displaced is used to quantify the cumulative amount
of AC activity (Nebes et al, 2007).
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Table 2: Methods of Burden Determination
Method

Year

Basis

Rating
Scale

Calculation

Evidence

Practical in Clinical
Setting

Serum
Anticholinergic
Activity (SAA)

1970's

Radio-receptor
Binding Assay

n/a

Amount of 3H-QNB
displaced

Gold Standard

No

2002

Atlas of
Psychiatric
Pharmacotherapy

sum of all drug scores

AC burden
significantly
associated with
falls

Yes

sum of all drug scores

AC burden
associated with
SAA values

Yes

Yes

Yes

Anticholinergic
Burden Scale
(ABS)
Anticholinergic
Drug Scale
(ADS)

0-5

2006

SAA

0-3

Anticholinergic
Rating Score
(ARS)

2008

Expert based;
disassociation
constant for
cholinergic
receptor, rate of
AC adverse
events, and the
literature

0-3

sum of all drug scores

ARS score was
associated with
an increased risk
of
anticholinergic
adverse effects

Clinician Rated
Anticholinergic

2008

Expert based;
reported AC

0-3

sum of all drug scores

AC burden was
significantly
associated with
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Method

Year

Basis

Scale

activity

Anticholinergic
Cognitive Burden
(ACB)

Expert-based;
severity of drug’s
AC activity on
cognition using a
scale based on the
literature between
1997 and 2007

Drug Burden
Index (DBI)

2009

2009

FDA Approved
doses

Rating
Scale

Calculation

Evidence

Practical in Clinical
Setting

decreased
executive
functioning and
increased
memory
impairment

0-3

n/a

sum of all drug scores

AC burden not
associated with
engagement or
mental status

Yes

[(sum of daily doses)/
(sum of daily doses + min
efficacious daily doses)]

AC burden was
associated with
worsening
function using
gait speed and
grip strength

Yes/No
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The binding is expressed in atropine equivalents, with higher atropine equivalents conveying a
greater likelihood of AC properties of drugs and metabolites in serum (Nishtala et al, 2009).
Research has shown that the use of SAA is an appropriate method to calculate AC burden in
older adults. In a study of community-based elderly aged 70+, SAA was associated with the
Mini-Mental State Exam (MMSE) scores. Those who had SAA levels in the 90th percentile and
greater were 13 times more likely to have MMSE scores that were less than 24/30 compared to
subjects who had no measurable SAA. Even low SAA was associated with cognitive impairment
(Kay et al, 2005A; Mulsant et al, 2003).
The assay does have limitations however. Serum is not always representative of what is
occurring in the brain. Plaschke et al investigated this relationship between AC activity in the
cerebral spinal fluid (CSF) and blood. A competitive radioreceptor binding assay was used.
They found that mean AC levels in the blood were 2.4 ± 1.7 pmol/mL and 5.9 ± 2.1 pmol/mL
atropine equivalents in the CSF. AC activity was found to be 2.5-fold higher in the CSF. There
was a significant linear correlation between blood and CSF levels. Therefore, it was determined
that SAA does reflect central anticholinergic activity (Brecht et al, 2007). Furthermore, SAA
does not appear to be affected by surgery or clinical care (Brecht et al, 2007). Contrary to these
results, Mach et al found that SAA was elevated in patients who were delirious compared to
those who were not (Mach et al, 1995). Therefore SAA may be affected by acute illness. Also,
SAA is a tool that may be used to assess delirium. A study by Flacker et al. used a radioreceptor
assay to assess delirium in 67 patients. They found that delirium was associated with higher
SAA and there were a higher number of delirium symptoms associated with a higher SAA
(Flacker et al, 1998). Other studies have used SAA to investigate the association of AC burden
with functional outcomes. In the study by Nebes et al, participants were divided into low,
15

medium, and high SAA groups (Nebes et al, 2007).

Participants underwent a walking

assessment in which they had to walk a 15-foot course on carpet. Response time was assessed
by pressing a button when they saw a one centimeter dot appear on a computer screen. After
controlling for sex and age, the high SAA group (>1.9 pmol/mL) had significantly slower walk
times and response times. It is suggested that the psychomotor slowing that occurs at high SAA
levels may predict balance issues and falls (Nebes et al, 2007). Furthermore, several studies
have shown the association between SAA and adverse CNS effects (Nishtala et al, 2009). This
includes a study by Chew et al who used SAA to measure AC activity of the 107 most frequently
dispensed medications used by older adults in long term care (Chew et al, 2008).
Pharmacokinetic data was used to estimate the dose and AC activity relationship.

The

investigation found that 39 of the 107 medications showed detectable AC activity. Medications
found to have a high AC activity, which was determined as a concentration of greater than 15
pmol/mL atropine equivalents, included amitriptyline, doxepin, clozapine, thioridazine, atropine,
dicyclomine, L-hyoscyamine, and tolterodine. All 13 of the drug classifications evaluated had at
least one drug that had AC activity at its therapeutic dose (Chew et al, 2008). While SAA is an
appropriate way of determining AC burden, it is not the most practical in clinical settings. This
laboratory assay is lengthy and requires a blood sample. This may prove difficult in older adults,
especially those with dementia. Moreover, SAA cannot be readily performed in nursing homes,
assisted living facilities and other locations where a calculation of burden would be helpful to
prevent negative drug consequences because the assay is not widely available in commercial
clinical laboratories.
Recently, several rating scales to assess burden in an efficient way have been developed. One
such scale is the Anticholinergic Burden Score (ABS). The ABS is an additive score based on
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quantitated AC effect of each psychotropic compound a patient receives. This quantitated AC
effect is rated on a scale of 0 (no AC effect) to 5 (highly AC effect) based on information
published in the “Atlas of psychiatric pharmacotherapy” (Shiloh et al, 1999).

For example a

medication such as amitriptyline has a value of 5 and risperidone or fluoxetine is a 1. In a study
by Aizenberg et al, ABS was used to evaluate the effect of AC burden on falls. The ABS for
each of the 102 patients was calculated. There were 34 patients who had a recorded fall and the
ABS was calculated on this day. The mean ABS score for all of the patients was 2.68 ± 1.8 and
for those patients that suffered falls was 3.25 ± 2.2. This value was significantly different from
those who did not suffer a fall. This scale does not take the dose or dosing regimen into account.
In addition, the basis for the rating scale is from a book and on the pharmacological mechanism
of action (Aizenberg et al, 2002). Additionally, the referenced version of the text was not
available. Therefore, the method of how the quantitated AC effect was determined was not
understood.

Another scale is the clinician-rated anticholinergic score.

This scale is different from the

previous one in that it incorporates expert opinion. This scale was originally developed to assess
potential effects of AC medication use on the severity of delirium symptoms. Scores range from
0, no effect, to 3, strong effect. The rating procedure and resultant AC drug list were based on
the Summer’s Drug Risk Number (DRN), where 62 medications were classified as 0 to 3. This
was published in 1978. To update the list, 340 medications with reported AC activity as well as
those used in the study population from the Han et al study in 2001 were included. Then 3
geriatricians independently rated the AC effect of each medication from 0 to 3 based on their
clinical experience, knowledge of the properties of the drugs and the American Hospital
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Formulary Service system.

The median of the 3 ratings were adopted. All medications were

counted, both AC and non-AC, in this method. Previous studies have shown that this rating
scale has good criterion and predictive validity with the SAA. There were 544 participants
enrolled in the Han et al. study, of which 342 or 62.9% used AC medications (Han et al, 2008).
The study evaluated the longitudinal effect of cumulative AC drugs on memory and executive
functioning. The mean clinician-rated AC score was 1.3 ± 1.5 for all 342 participants. The most
frequently used medications that had a score of 2 or 3 included ranitidine, amitriptyline and
fexofenadine. AC burden was significantly associated with decreased executive functioning and
increased memory impairment (Han et al, 2008).

An additional scale was developed by Rudolph et al to assess the risk of adverse drug events
(ADE) caused by AC medications. ADEs included central effects such as falls, dizziness, and
confusion and peripheral effects such as dry mouth, dry eyes, and constipation.

The

Anticholinergic Risk Scale (ARS) ranks medications with AC potential on a scale of 0, limited or
no AC potential, to 3, very strong AC potential. This rating scale is similar to the clinician-rated
AC scale in terms of the scoring and the use of experts. Specifically, geriatricians and geriatric
pharmacists determined the rank of each AC drug. These experts reviewed the disassociation
constant for the cholinergic receptor, rate of AC adverse events, and the medical literature for the
most prescribed medications (Rudolph et al, 2008). Rudolph et al. conducted a two part study;
the first was a retrospective review of medical records for AC adverse effects and for
medications included on the ARS. The second part was a medication reconciliation and review
of the documented AC adverse effects. The study found that a higher ARS score was associated
with an increased risk of AC adverse effects for both cohorts (Rudolph et al, 2008).
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The Anticholinergic Cognitive Burden (ACB) Scale is the third scale that is based on evidence in
the literature and expert clinician input (Kolanowski et al, 2009). Additionally, it has a focus on
central AC effects only.

It is an expert-based index that classifies the severity of a drug’s AC

activity on cognition using a scale that is based on a review of the literature between 1997 and
2007. Specifically studies that measured the AC activity of drugs and their cognitive effects
were reviewed.

The collected list of medications were then reviewed by an expert

interdisciplinary team and categorized as mild, moderate, or severe. These three ratings were
then translated to 1, 2, and 3.

Total ACB was calculated by summing the ACB scores of all

scheduled drugs prescribed for an individual. The study by Kolanowski et al. used this method
to determine the association of AC burden and engagement in activity in nursing home residents
(Kolanowski et al, 2009). The study found that 81.6% of the Pennsylvania nursing home
patients took at least 1 AC drug. Additionally, 56.3% were prescribed two or more AC drugs.
There were a total of 28 AC medications that the patients were taking with furosemide and
metoprolol as the most commonly prescribed. The authors concluded that decreased mental
status was associated with engagement outcomes, but AC burden scores were not (Kolanowski et
al, 2009).
Carnahan et al also developed a rating scale, the Anticholinergic Drug Scale (ADS), using
ratings of 0 to 3, with level 0 = no known AC properties; level 1 = potentially AC as evidenced
by receptor binding studies; level 2 = AC adverse events sometimes noted, usually at excessive
doses; and level 3 = markedly AC (Carnahan et al, 2004). This quantification of AC burden was
found to be significantly associated with SAA. Their study also supported the separation of ACs
into categories based on AC potency. Overall, the findings of Carnahan et al suggest that ADS
may be a tool for assessing AC burden (Carnahan et al, 2004).
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This tool is unique in that it

includes both as needed medications, PRN, and scheduled. In addition, the authors replicated the
study, but with modifications to evaluate the association with SAA. The modifications included
adjusting for dose. The maximum recommended daily dose for each medication on the list was
determined using the product labeling approved by the Food and Drug Administration. The
maximum dose was compared to the dose that the participants were taking. Weights were
applied to the participant’s dose and ranged from 1 to 4. For instance, if the dose was less than a
third of the maximum then it was weighted as 1 and if it was greater than the maximum
recommended daily dose then it was weighted as 4. With this modification, the analyses found a
significant association with SAA, but not significant compared to the non-modified scale
(Carnahan et al, 2006). While not significant in this study, dosing still explained more of the
variation seen by the model than by not including it. Furthermore, dosing is important in
calculating burden as a higher dose leads to more exposure and a greater level of AC activity.
The last and most recent scale is the Drug Burden Index (DBI). The DBI measures overall
exposure to medications with AC and sedative properties. This scale includes the daily dose of
the AC medications and the minimum efficacious daily dose approved by the FDA. The total
drug burden is equal to the sum of the daily dose for a medication divided by the sum of the
minimum efficacious daily dose and the daily dose, for both sedatives and ACs.

All

medications, except topical ones without significant systemic effects were included. In the study
by Hilmer et al, the index was used to evaluate the relationship between physical and cognitive
performance and medication use (Hilmer et al, 2009). The study found that higher drug burden
was associated with worsening function using gait speed and grip strength.

Moreover, a one

unit increase in the DBI predicted a significant decrease in gait speed of 0.04 m/s, which is more
significant than the additional decline in physical or mental comorbidity (Hilmer et al, 2009).
20

While the use of laboratory measurements that measure AC activity in the CSF is the best
followed by a tool such as SAA, it is not practical in most clinical settings. In addition, it is not
only time-consuming but also expensive. Furthermore, alternative methods such as the use of
one of the many scales may be more appropriate for special populations such as patients with
dementia. All of the scales except for the DBI do not take into consideration of the dose.
Additionally, only the ABS and the DBI do not use a 0/1-3 scale to categorize the medications.
While the DBI has significant benefits over the other scales as it takes into consideration the
dose, it is more difficult and time-consuming compared to the other scales. Therefore it may not
be entirely practical in a busy long-term care or hospital setting. When the other scales are
compared against each other, the ABS is advantageous as it provides a wider scale in which to
categorize drugs (0-5), but its basis is a textbook. The Clinician Rated Anticholinergic Scale and
the ARS are almost identical. The ACB is different by including only those with central effects,
this a disadvantage compared to the others. The ADS is older compared to the other scales
except for the ABS, and is based on the SAA, which while it is an imperfect measurement, it is
still better than using expert opinion alone or not including AC potency as a component of
burden measurement.
1.2.2 Prevalence of Use
Several studies have shown that older adults are at greater risk of developing negative side
effects from prescribed and over the counter medications that have AC properties. Furthermore,
in some cases these side effects may be attributed to worsening dementia or the increase risk of
cognitive impairment, falls and functional decline (Robinson et al, 2009; Han et al, 2008). These
negative cognitive effects include impairment in working memory, episodic memory, processing
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speed and praxis.

Moreover, use of AC medications is a significant predictor of overall

performance on general activities, mild cognitive impairment and delirium (Chew et al, 2008). It
is important to note that AC drugs have both central as well as peripheral side effects, including
confusion, sedation, loss of concentration, hallucinations, and delirium. In older adults with
dementia these effects may be magnified (Modi et al, 2009). Older adults are more likely to
have multiple chronic diseases and therefore receive multiple medications. Also, there is an
increasing trend of drug usage in older adults, even without the addition of chronic diseases (Han
et al, 2008). In many cases more than one AC medication is prescribed to the same older adult.
Also, they are more likely to receive a medication with AC effects. Studies for decades have
shown that older adults receive a large number of medications with AC effects. A summary of
the prevalence studies is provided in Table 3. A study in 1983 found that approximately 60% of
nursing home patients and 40% of ambulatory patients received a medication with AC properties
(Feinberg, 1993). More recent studies have indicated that as many as 27% of community
dwelling adults are using AC medications (Merchant et al, 2009). Furthermore, a study by Han
et al. found that more than 30% of nursing home residents take two or more AC drugs and
estimated that this number was closer to 50% in the general population (Han et al, 2008).
Another study in France found that the 327 older adults who were continuous AC users had
poorer performance on cognitive tests at 1 year than non-users (Ancelin et al, 2006). In the study
by Han et al, 342 (62.9%) of 544 subjects were using AC medications. The number of subjects
using these medications increased to 364 and 378 in the following years. The mean AC score
was 1.3 ± 1.5 and a median of 1.0. The most commonly used AC medications had moderate to
strong effects.

These included ranitidine, amitriptyline, fexofenadine, nortriptyline, and

paroxetine (Han et al, 2008).
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Table 3: Summary of Prevalence Studies
Author; Year

Population

Result

Blazer 2 et al;
1983

5,902 nursing home
residents and 5, 861
ambulatory subjects of
Tennessee Medicaid
recipients ≥ 65 YO

59% of nursing home residents
and 23% of ambulatory
subjects received at least 1 AC
drug

LechevallierMichael et al.;
2004

1780 subjects aged 70 and
older, living at home in
South western France

13.7% of the subjects used at
least one drug with AC
properties

Ness et al; 2006

532 patients from the Iowa
City VAMC

27.1% used at least 1 AC drug

Johnell et al;
2007

732,228 adults ≥75 YO
from the Swedish
Prescribed Drug Register

6% were prescribed AC drugs

Han et al; 2008

544 community dwelling
men ≥ 65 YO with
diagnosis of hypertension

62.9% were using AC
medications

Lakey et al.;
2009

174 recipients of home
health services in Eastern
Washington State

80.0% were using a
medication with AC effects;
66.1% were using weak AC
and 33.8% potent agents

Olsson et al.;
2010

3705 residents in nursing
homes and special
dementia units in a
Swedish county

20.7% in nursing home used
AC drugs; 18.5% in dementia
units.

Kumpula et al.;
2010

1004 residents of a
Helsinki, Finland longterm care ward in 2003

36% mild AC burden (ARS
score = 1-2); 19% high AC
burden (ARS score ≥ 3)

nd
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In addition, Blazer et al. in 1983 determined in their study that between 21% and 32% of elderly
patients living in nursing homes were using two or more AC drugs. Ten to 17% of nursing home
residents were using > 3 ACs and up to 5% of nursing home residents were using > 5 ACs.
Regarding combination medication formulations, the most frequently used combinations
included thioridazine/benzhexol and thioridazine/chlorpromazine (benzhexol is rarely used now).
Also, the use of thiordiazine concomitantly with amitriptyline was prevalent, which may signify
that there was a lack of alarm on the part of the prescribers and other involved healthcare
professionals about the overall summation of AC effects. One study found that by administering
AC medications, delirium could be induced and then reversed by administering cholinergic
agonists (Han et al, 2008). Similarly, Spore et al. determined that 43% of elderly patients in
nursing homes were taking psychotropics (Mintzer et al, 2000). Studies suggest that drugs with
AC effects may reduce the effectiveness of AChEIs when they are taken together (Carnahan et
al, 2002).

In addition, the combined use has the potential to increase the rate of cognitive

decline in patients and affect the severity of delirium symptoms that may be present.

In

dementia and AD, AC medications are prescribed for the treatment of comorbid conditions
associated with dementia. In addition, they may also be used to treat the side effects of AChEIs
in a prescribing cascade. Studies have shown that the concomitant use of AChEIs and AC
medications is not uncommon. A study by Roe and colleagues found that older adults with
probable dementia were more likely to use moderate to strong AC medications compared to
matched controls (Roe et al, 2002).

In addition, Carnahan and colleagues measured the

prevalence of AC use in Iowa Medicaid beneficiaries over the age of 50 who were on AChEIs.
They also evaluated the change in use of the ACs when an AChEI was started. They found that
approximately 36% of the patients were using both classes at the same time. In addition, about
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75% of the AC medications were considered highly AC with known adverse events associated.
The incidence of AC use when an AChEI was started increased in the study participants
(Carnahan et al, 2004). Another study found that 1/3 of community dwelling older adults with
dementia were taking AChEIs and AC medications concomitantly. Modi et al in 2004 found that
46.7% of the Indiana Medicaid population was taking the two classes together. Furthermore, of
this concurrent population, 58.1% were taking a medication classified as markedly AC. H2
antagonists, respiratory antihistamines and urinary antispasmodics were the three most
commonly prescribed AC medication classes (Nebes et al, 2007). Other studies have shown that
older adults with dementia are at an increased risk of the receiving an AC medication (Gill et al,
2005).
It is suggested that the cause for this phenomenon is the side effects associated with AChEIs and
comorbid conditions associated with AD. Older, less expensive drugs are more likely to be
prescribed due to economic reasons or prescription biases. The older, less expensive drugs
include tricyclic antidepressants which are known to have high AC effects (Inouye, 1999). Roe
and colleagues concluded that based on the potential for antagonism between AChEIs and AC
medications that even short-term use is contraindicated (Roe et al, 2002). Interestingly enough,
trials for donepezil, rivastigmine and galantamine did not allow participants to be on AC
medications. Determining whether a patient will develop or experience adverse effects to AC
medications depends on several factors including total AC load, cognitive functioning, and
individual pharmacokinetic and pharmacodynamic variability (Roe et al, 2002). There is some
evidence in the literature about the effects of concurrent use. In one study, 69 AD patients taking
AChEIs and AC meds chronically had greater cognitive decline at 2 years than those not taking
ACs (Han et al, 2008). There is some evidence that the concomitant use of AChEIs and AC
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medications may decrease the effectiveness of AChEIs. Even with this preliminary evidence it is
not uncommon for the two medication classes to be prescribed together (Modi et al, 2009).
In addition, to being more likely to receive an AC medication, the demented population is more
likely to suffer from adverse events and reactions due to AC medications (Thienhaus et al, 1990).
It is suggested that demented patients are significantly more vulnerable than non-demented in
cognitive effects of AC medications, possibly due to the central cholinergic deficiency
(Doraswamy et al, 2006). In addition, studies have shown that the risk of adverse cognitive
effects increases with total AC burden or load and that these medications have the potential to
worsen symptoms (Roe et al, 2002; Tune et al, 2003). It is possible for a dementia patient to
suffer from AC toxicity, which is characterized by signs and symptoms of dysfunction of the
parasympathetic system and the brain. These signs and symptoms include decreased attention
span, disorientation, psychotic features and psychomotor agitation. All of these symptoms can
lead to functional impairment (Thienhaus et al, 1990). In a study by Thienhaus et al, demented
participants displayed significant impairment in association with higher AC serum activities
compared to non-demented patients (Thienhaus et al, 1990). The AC serum levels that were
associated with significant deterioration of selected cognitive functions caused no dysfunction in
the 18 non-demented subjects.

Measures of recognition, concentration and retrieval of

information (corresponds to deterioration of knowledge memory) all decreased significantly with
higher AC serum levels (Thienhaus et al, 1990).

Other studies have shown worsening

performance on reaction time, attention, face and narrative recall, and visospatial and language
abilities (Doraiswamy et al, 2006). A study by Jewart et al. showed that when dementia patients
were taken off AC medications, specifically incontinence medications, they demonstrated better
performance on tests of mental status and behavior (Jewart et al, 2005).
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1.2.3 Outcomes of Use in Older Adults
There are over 600 medications that have AC properties (Tune et al, 1999), some with intended
effects and others that are unintended. Furthermore, Tune et al. tried to determine serum AC
activity of the 25 most frequently used drugs in the elderly. They found that 14 of the total 25
drugs had some level of AC activity. Ten of these drugs, which included ranitidine, codeine,
dipyridamole, warfarin, isosorbide, theophylline, nifedipine, digoxin, and prednisolone, caused
significant impairment in recent memory and attention in psychiatrically healthy elderly subjects
(Tune et al, 1992). Often times, several ACs were given concurrently (Mintzer et al, 2000; Tune
et al, 1992). Scopolamine is strongly AC and it is suggested that it specifically targets muscarinic
receptors. Other medications such as the antibiotic piperacillin, has unintended AC effects.
According to the package insert, piperacillin is a bactericidal drug that works by inhibiting
septum formation and cell wall synthesis of bacteria (Zosyn Package Insert, 2009). The package
insert does not include the AC properties of this medication. Yet, validated laboratory assays,
such as the serum anticholinergic activity assay, SAA, have ascertained that this is the case
(Mintzer et al, 2000; Tune et al, 1999). This assay has been shown to be a better predictor of
cognitive impairment than age or the total number of drugs that a person takes (Chew et al,
2008).

The lack of knowledge about the AC properties of medications may be due to

insufficient information about how most prescription and over-the-counter drugs as well as their
metabolites affect the cholinergic system.

Therefore, just knowing a medication has AC

properties does not provide the full picture (Chew et al, 2008).

Overactive bladder is a good

example of this situation. It is a disease state that is common in older adults with dementia, with
some estimates as high as 53%.

Other reports place this number between 11% and 90%

depending on the methods of estimation and the definition of urinary incontinence (Yap et al,
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2006).

Much of the incontinence in dementia is functional, which refers to incontinence

associated with physical disabilities, external obstacles or mental disabilities.

Antimuscarinic

medications are the pharmacological treatment for overactive bladder. These agents work by
blocking the effects of acetylcholine at muscarinic receptors, specifically of the bladder. Hence,
there is a reduction in the frequency and intensity of involuntary detrusor contractions. Research
has shown that the M2 and M3 subtypes are located within the detrusor muscle, specifically the
M2 receptor predominates with a 3 to 1 ratio. Furthermore, it is the M3 subtype that is mostly
responsible for muscle contraction. While the specific action of these antimuscarinic agents is to
target the M3 receptors, they have the potential to bind to all of the muscarinic receptors,
including M2 and M1. Therefore, they have the potential to cause adverse events. In addition,
they have the potential to worsen or negatively impact chronic diseases. There are reports and
evidence in the literature of memory loss, confusion and delirium with the use of non-selective
muscarinic receptor antagonists (Kay et al, 2005A).

Furthermore, these neuropsychiatric

adverse events may be underreported as they may be considered part of normal aging (Kay et al,
2005A).
1.2.4 Outcomes of Use in Dementia
In dementia patients AC toxicity can result in morbidity and mortality, behavioral symptoms and
delirium. Studies have found correlations between serum AC levels and functional disability,
agitation and delirium (Carriere et al, 2009). Delirium and confusional states are common in
dementia and associated with mortality rates up to 40%. In terms of cost, delirium is estimated
to account for more than $32 to $152 billion each year, according to a 2008 study (Leslie et al,
2008).

In addition, there are costs for increased hospital stays, nursing home placement,
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rehabilitation services and home health care (Inouye, 1999). Dementia is one of the strongest
risk factors for the development of delirium. In addition, the severity of the dementia correlates
to the risk for delirium. However, detection of delirium in dementia is only in about 12% to 31%
of all cases. It is also known that patients with dementia have a significantly longer episode of
delirium compared to those who do not have dementia (Lim et al, 2006). One study showed that
approximately 40-50% of patients with dementia had persistent delirium for 6 to 12 months
(McCusker et al, 2003).

Delirium and dementia are both associated with cholinergic

disturbances, but the difference is that delirium is an acute condition that may occur if a person
has dementia (Tune, 2001). There are three types of delirium: hyperactive, hypoactive and
mixed delirium. The first and third are often associated with cholinergic toxicity. Some studies
suggest that up to 11.5% to 39% of all delirium in AD patients is due to medications.
Medications that are known commonly to cause delirium include high dose narcotics,
benzodiazepines and ACs. In addition, to the medications listed above, lithium has been linked
to delirium in dementia patients (Alagiakrishnan et al, 2004). Other outcomes reported in studies
include falls and geriatric syndromes (Tune et al, 1999). Therefore, the use of AC medications
with AChEIs in patients with AD has the potential for serious negative outcomes and may
decrease overall effectiveness of AChEIs.
1.3 Barriers to Research Participation in Alzheimer’s Disease Studies
The research that has been conducted and continues to be conducted in this area is mostly
observational. According to the current standards, a randomized controlled interventional study
to reduce AC burden would provide a more definitive conclusion on the impact of AC burden on
dementia patients.

One reason that these studies have been difficult to perform is patient
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recruitment. Recruiting patients is a difficult process and there are many barriers that need to be
overcome for this to occur. This section will discuss the barriers associated with recruiting older
adults to participate in clinical studies.
Several studies have documented that older patients are underrepresented in clinical research.
There are a growing number of older adults in the population, which represents a serious
dilemma for translating research into clinical practice (Marcantonio et al, 2008). This is apparent
in Alzheimer’s research as well. Unfortunately, recruiting any sample of older adults, especially
AD participants, into clinical research is difficult, time consuming, and expensive. Some studies
have investigated the reasons behind low participation and found that older adults who refuse to
participate in research tend to be male, to be older, and belong to a lower income group (Arean et
al, 1996). This is true for AD studies as well. In a 1997 study by Schneider and colleagues the
entry criteria for industry sponsored AD clinical trials preferentially selected wealthier, more
educated and white individuals (Olin et al, 2002). Research has also identified several barriers
that exist to older adult and Alzheimer’s disease participation in research, but population size and
availability are not issues. Barriers can be divided into universal, minority, and researcher
specific.

1.3.1 Universal Barriers

There are many universal barriers including spousal support, location, transportation, caregivers,
the design of the research project, and knowledge of the study. Universal barriers include lack of
spousal support. Interviews show that if the spouse does not approve of the study or the research
than the possible participant will not volunteer. Approximately 55% of potential participants
indicated that they would decline if their spouse was not interested or did not approve
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(Marcantonio et al, 2008). For minorities, not involving the family or the spouse in the study and
the recruiting process may lead to fear and distrust of the research. Research has shown that as
many as 32% of potential participants refused to participate in research because their families
and physicians discouraged them (Arean et al, 1996).

Another barrier is location and

transportation, traveling to a hospital or a place that is not a residence may lead to a participant
declining. In a study by Marcantonio et al in 2008, 98% of the 50 older adults surveyed declined
participation in a study if they had to go to a hospital (Marcantonio et al, 2008).

For some

participants the research projects may not be held in communities where they live. Physical
limitations such as disabilities and health concerns as well as living in unsafe areas may preclude
participation. It is well known that older adults tend to have more health problems and be
disabled compared to younger counterparts. In addition, those with dementia are more likely to
have other comorbid conditions and require other transportation. Also, many settings may not be
ideal as participants may not want their friends and families to know that they are participating in
research or that they have a specific condition.

In a 1993 study by Arean et al, 99% of the

referrals from a senior center preferred participating in a university setting because they were
afraid that their friends would find out (Gelman, 2010). Another factor is care-giving, in which
some older adults may be caregivers from their own aging parents, spouses, or children. This
may hinder their ability to take time to travel to a hospital site or even afford transportation
(Marcantonio et al, 2008). In addition, Marcantonio and colleagues found that type of research
also plays a role.

Research that involves an invasive procedure is less likely to acquire

participation. Of the 50 participants interviewed 61% declined if a lumbar puncture was included
(Arean et al, 1996). Even more basic than the type of research is knowledge about the project.
Many potential participants may not even be aware of the opportunities for research. Advertising
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in older adult specialty newspapers or in local senior centers may be a useful method. Enlisting
the help of physicians and other healthcare professionals may also be useful. For minorities,
having a community leader that they trust disseminate the information about the study or
translating the advertisements in native languages may overcome this barrier. Another common
barrier is a long study period. A study that requires multiple visits or has a long duration will
dissuade possible participants. The desire to “be around” when the results are published or
shared is very important. There is some thought that the longer the duration of the study, the less
likely that they will be around for it (Marcantonio et al, 2008), (Arean et al, 1996).

Other

barriers to research, especially AD research, include caregiver stress, denial that there is a need
for help, view that reimbursement is not worth it, multiple diseases and limited functional
abilities, denial of vulnerability, lack of personal benefit and fear of adverse reactions (Souder et
al, 2007). In addition, distrust of research, lack of confidentiality, fear of safety, schedule
conflicts, poor access to medical care, and lack of knowledge were identified by UyBico et al in
2007.

Lastly, many older adults may not consider participating in research a worthwhile

expenditure of energy and time when they are already burdened with multiple stressors (Arean et
al, 2003).

1.3.2 Race and Minority Barriers

Race and minority status is a controversial barrier to participating in research. While many
studies have identified Hispanic and Black individuals with AD as an underrepresented group
that faces many barriers to participating in research, other studies have found that belonging to
an ethnic group was not significantly related to responding to or dropping out of research. Arean
and colleagues pointed out that while these studies have not found a difference in the rates of
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participation in research among ethnic groups, the reasons for not participating, and therefore the
recruitment and retention strategies, do differ considerably between ethnic-minority and nonHispanic white older adults (Arean et al, 1996).

The one issue that is well understood is that

recruiting and retaining older minorities is much more complex than non-Hispanic whites. The
main barrier is centered on enthocultural beliefs, specifically beliefs of mental illness, helpseeking behaviors, and socioeconomic status. This barrier may manifest as fear and distrust,
transportation issues, lack of information about the disorder, negative cultural attitudes toward
AD and mental illness in general, and lack of knowledge about the benefits of participating
(Marcantonio et al, 2008).

One issue that was mentioned above is the language barrier,

especially for Hispanics and other minorities. A significant proportion of the current Hispanic
AD population are not fluent in English. However, many clinical trial sites lack Spanishspeaking staff, and many clinical trials lack materials in Spanish (Olin et al, 2002).
Transportation issues are universal, but one specific concern is a fear of potentially becoming a
victim of racially motivated crimes. Therefore many older minorities may be less motivated to
visit a center or location that is not within their neighborhood. Care-giving is a common
situation for many minorities and may prevent the caregivers to participate in research. Studies
have shown that many African American women have custody of their grandchildren and have to
meet the needs for these children as well as care for their own needs. These issues often resulted
in participants’ having difficulty in coming to treatment and coming for follow-up interviews
(Marcantonio et al, 2008). Education or information about the disorder is not a problem that
affects just minorities, but it is more common in this population. Studies have found that many
older adults are willing to participate in research studies but do not do so because they know
little about the disorder under investigation and of the possible benefits to participating in
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research (Marcantonio et al, 2008). Low literacy and lack of contacts with the medical system
contribute to low rates of participation, in addition, to delays in seeking medical attention.
Therefore, if a family is not seeking medical attention then they will unlikely know about
research opportunities and in many cases be excluded due to advance disease by the time
diagnosis is made (Souder et al, 2009). Low education and cultural factors lead to misguided
views of AD and mental illness.

For some minorities they view these disorders as a

multidimensional condition, consisting of religious, spiritual and environmental aspects.
Therefore, attempting to treat it in following western guidelines may appear to be degrading and
decrease minority participation (Souder et al, 2009). Cultural competence is one of the most
important issues to consider when conducting research with minorities. Research has shown that
efforts to recruit minorities without taking into consideration cultural factors can lead to failed
projects. It is well known that minorities are more likely to have stereotyped ideas about mental
health problems. Therefore, they are less likely to participate in research. These stereotyped
ideas about AD and other mental illnesses lead to associated stigmas and participant burden.
Stigma concerns of older minorities are different from their White counterparts. Many older
minorities are concerned with the impact a psychiatric diagnosis will have on the family’s
reputation (Souder et al, 2009). In addition, minorities have a tendency to view themselves as
sicker compared to their non-Hispanic White counterparts. This perceived level of health and
disability significantly influences participation in research (Marcantonio et al, 2008), (Arean et
al, 2003).

For Blacks, cultural attitudes may dictate that they cope with illnesses by taking care

of their relative within the family and social network, instead of using the medical community.
These beliefs also lead to a view that AD or other diseases are normal and natural occurrences
(Souder et al, 2009). Fear is another barrier that is not unique to minorities, but it appears
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differently in this population. Fear leads to mistrust of science and health services. For various
immigrant groups this fear stems from war related atrocities that were conducted in the name of
science.

In Blacks, the most significant barrier to participation stems from historical events,

such as the infamous Tuskegee Syphilis Study. These events have lead to the perception that
they are treated differently by medical professionals than their White counterparts due to their
race. Whether this is real or perceived racism, it still affects participation in research (Souder et
al, 2009).

The recruitment of special populations requires increased resources and time to

develop trust, knowledge of the culture, engagement of the community, and special strategies
targeted to the particular needs of the group.

Inability to recruit a sufficient number of

participants is a major reason for failures in clinical trials (Buckwalter, 2009).
1.3.3 Researcher Related Barriers
Researchers face many barriers to recruiting potential older adult AD patients as indicated above.
Overcoming participant views, attitudes and perceptions are important, but not the only barriers
faced when recruiting patients. Other obstacles include health information regulations, physician
and healthcare practitioner barriers, economic concerns and study design.

HIPAA, Health

Insurance Portability and Accountability Act, changed the way recruitment was handled by all
researchers. This regulation, specifically the Privacy Rule, took effect in 2003. This required
researchers to gain information about patients from a “covered entity,” specifically a health care
provider, health plan, or clearinghouse with access to the patient’s personal health information
(PHI). What this meant was that a health care provider had to identify potential participants and
ask them for written permission to give the researcher their name and phone number if they want
to learn more about a study. As a result, study recruitment is much more difficult (Sullivan35

Bolyai et al, 2007). Other barriers that stem from this regulation include “work burden.” Work
burden refers to working with busy clinicians to assist in recruitment. It is well known that
physicians and health care providers are extremely busy and have a large workload. Adding an
additional responsibility to this load can be very difficult and typically research ends up at the
bottom of the to-do-list.

In some cases research may be viewed as extra work without

compensation or perceived as taking time away from providing patient care (Sullivan-Bolyai et
al, 2007). In addition, research may be viewed as a financial disincentive if it diminishes clinic
profit by reducing the number of patients that can be seen. As mentioned above, physician and
health care provider bias towards the research can impact the willingness to participate by the
patient. The desire to protect their patients can also restrict patients’ rights and decision making
opportunities. A study by van Ryn and Burke (2000) found that physicians’ perceptions of
patients may influence whether they recommend the research (Sullivan-Bolyai et al, 2007).
These perceptions are influenced by the patients’ race and socioeconomic status. For instance,
physicians rated patients who were African American as less compliant. Health care providers
may be wary if they perceive a study could physically harm or put undue stress on their patients
(Sullivan-Bolyai et al, 2007). Other hurdles include competing service demands on the provider,
multicultural differences, lack of knowledge, bias against research leading to inactive
recruitment, overly restrictive eligibility criteria, complex IRB requirements, poor relationships
with the research team – leading to distrust of researchers and their motives, dislike of the
research procedures (Buckwalter, 2009; UyBico et al, 2007).
The literature illustrates that there are many barriers to conducting research in the older adult
population, specifically the AD population. There are many ways to overcome these barriers,
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but they are both time consuming and expensive. In addition, it is not always possible to
improve participant recruitment even if obstacles have been removed.
1.4 Chapter Summary
In this section a detailed summary of AD was provided including current treatments. ChEIs, the
current symptomatic treatment, has a pharmacological interaction with other medications,
specifically those with AC properties. Medications with AC properties are numerous and there
is much evidence that they cause negative outcomes in older adults. There is also some evidence
that they may cause negative outcomes in dementia patients. Additionally, the idea of AC
burden, the cumulative effect of the total AC medications that a person consumes, was
introduced and measurements of this burden described. While research in this area is constantly
increasing, most of the studies are observational. While a randomized controlled study would
provide important evidence as to the causal relationship, recruitment issues are a considerable
barrier to performing this type of research. Therefore the last section discusses the several
barriers that are involved including universal, race/minority and researcher related ones. These
barriers once taken into consideration and overcome will enable stronger studies to occur. In
Chapter 3 the preliminary research that has been conducted will be discussed. Two preliminary
projects are discussed, one that was completed and the other that was stopped due to low patient
recruitment. In Chapter 4, the methodologies for a retrospective database project conducted at
Piedmont Geriatric Hospital are described. Finally the results and the discussion are presented in
Chapters 5 and 6, respectively.

37

Chapter 2
Significance and Specific Aims

2.0 Significance
AD and dementia in general are incurable diseases with no disease modifying treatments
available. As the disease progresses, great medical and social changes occur. The cognitive
deficits that develop limit patients’ ability to understand written information and participate in
consequential conversation. The limited social activities due to deficits in function may increase
the risk of illnesses and poor health that may trigger negative behaviors and increase medication
uses. Additionally, there are negative changes in behavior caused by the inability to articulate
discomforts or frustration. Behavioral problems can increase the risk of receiving harmful
medications (Forchetti, 2005). Working with moderate to severe dementia patients can be
difficult, which may be one reason why there is little research in this population.
While most families prefer to keep their loved ones at home for as long as possible, many
moderate to severe dementia patients live in long-term care facilities or hospitals. A 2008 study
found that 68% of all nursing home residents had some degree of cognitive impairment
(Alzheimer’s Association 2010). Additionally, 41% of those older adults had moderate to severe
impairment (Alzheimer’s Association 2010).

Therefore it is important to study dementia

patients in institutionalized care.
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The current standard of care with the use of cholinesterase inhibitors (ChEIs) and memantine, is
very expensive and provides only modest improvements. Only ChEIs have an indication for mild
disease, but both ChEIs and memantine have indications for moderate and late disease. While
there are some studies that suggest positive outcomes from the use of these medications in late
disease, there are also studies that show no significant outcomes (Forchetti, 2005). Furthermore,
research has shown that receiving a cholinesterase inhibitor increases the likelihood of being
prescribed an AC medication (Gill et al 2005; Robinson et al, 2009). Moreover, the concurrent
use of the two classes of medications is not an uncommon occurrence (Feinberg, 1993). This
combined use may reduce the benefit of the ChEIs as these two classes have opposing
pharmacological mechanisms of action.

There are epidemiological studies that show that

concurrent use of these two classes has the potential to cause harm to AD patients (Han et al,
2008). The ChEI approval trials excluded AD patients taking AC drugs; therefore there is no
evidence to support the concurrent use of these two classes of medications as part of FDAregulated drug development.
Time is also a significant factor in dementia. Each dementia patient is different in how they
progress through the disease. Some progress more rapidly than others and some have more
behavioral or functional problems than others. By collecting data over a period of time, one is
able to better understand and correlate the effects of medications and other factors on health and
social outcomes. Therefore, research in dementia patients should consider change over time
rather than a single point in time (Twisk, 2003).
This study is based on the hypothesis that drugs with AC effects impair function, memory, and
behavior in dementia patients. Furthermore, the concurrent use of AC drugs with ChEIs impairs
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the efficacy of drug therapy in patients taking ChEIs.

While most studies focus on the

cognitive effects of AC burden and concurrent use, few investigate functional and behavioral
outcomes. It is believed that AC effects on dementia may lead to a faster decline in cognition,
function, and behavior based on the evidence from the use in psychiatrically stable older adults
(Tune et al, 1992)

It is expected that this decline will be seen in the patients taking ChEIs as

they are more likely to receive an AC drug and subsequently higher anticholinergic burden that
would counteract the effects of ChEIs. Hence, the greater the burden it is expected the greater
the decline in function, cognition, and behavior over time.
2.1 Specific Aims
The specific aims of this study are:
o To quantify anticholinergic burden in moderate to severe dementia patients
receiving long term treatment in a state geriatric psychiatric hospital.
o To assess the function in dementia patients with varying anticholinergic burdens
due to their concurrent medications.
o To assess the cognition and behavior in dementia patients with varying
anticholinergic burdens due to their concurrent medications.
o To identify anticholinergic medication- and patient-related factors relevant to
functional outcomes in dementia patients taking anticholinergic drugs.
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Chapter 3
Preliminary Research

3.0 Chapter Introduction
In this chapter two preliminary studies investigating AC use will be discussed. The first study is
a retrospective analysis of the University Health-System Consortium database, investigating the
prevalence of AC drug use in older adult inpatients without dementia.

This study is still

ongoing, therefore only preliminary results are provided. The second study was a prospective
analysis of functional, behavioral, and cognitive functioning in older adults with mild to
moderate AD. This study was stopped prematurely due to the difficulties in recruitment of study
participants.
3.1 Anticholinergic Drug Use in the Hospitalized Elderly
3.1.1 Background and Significance
AC medications inhibit or block the actions of acetylcholine in both the peripheral and the
central nervous system. Wide varieties of medications possess AC properties and are frequently
prescribed for health conditions common in the elderly. The medications can have a cumulative
effect that may cause early cognitive declines (Kay et al, 2004). Older adults are vulnerable
because of the decrease in effectiveness of the blood-brain barrier, changes in body composition
and altered drug elimination pathways.
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This in conjunction with reductions in metabolism and elimination increase the risk for adverse
AC effects. The central nervous system dysfunction is shown by changes in memory, disruption
of sleep, hallucinations, confusion and delirium that could lead to an increase in hospital stay
(Kay et al, 2004).
The specific aims of this project were to study the prevalence of AC drug use in non-demented
elderly inpatient population, to observe the most commonly used AC medications and to study
the relationship between length of stay and AC burden. Based on the available evidence we
hypothesized that the prevalence of AC drug use was common and that those patients taking
these medications would have a longer length of stay.
3.1.2 Methods
3.1.2.1 Data Source
The data was obtained from the University Health-System Consortium (UHC) Clinical Database
(CDB), which is an alliance of 90 academic health centers in the United States. The UHC CDBPharmacy database contains procedure and diagnosis-specific data from discharge abstract
summaries, Universal Billing Code of 1992 (UB-92), and medication use data from charge
transaction masters and patient billing files for all inpatients at participating centers. The UB-92
is a standardized database used by hospitals to generate itemized charges for patient visits. One
year of data was evaluated from October 2003 to September 2004. This study was reviewed by
the Virginia Commonwealth University (VCU) Office of Research Subject Protection
Institutional Review Board (IRB) and found to qualify for exemption from federal regulations
requiring IRB review and approval. The study population included hospitalized patients 65 years
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of age or older with no evidence of dementia. Evidence for dementia included ICD-9 codes for
any type of dementia illness or receiving a ChEI.
3.1.2.2 Data Collection
Several variables were collected from the database including the medications that a patient was
receiving, age, sex, race, observed hospital length of stay (LOS), AC drugs, severity score
(evaluation of severity of illness and risk of mortality), whether they were discharged to a
nursing home and the presence of delirium based on ICD-9 codes. The ICD-9 codes included
292.81 (drug-induced delirium), 293.0 (acute delirium) and 293.1 (subacute delirium).
Calculated variables included AC medication use, AC burden, and AC potency. The outcome
variable, LOS, was not normally distributed and was log-transformed. AC medication use was
coded as yes/no and was determined for each patient in each group. The AC medications with
CNS activity included in this review are listed in Table 4. Combination drug products containing
one of these ACH drugs were also evaluated.

For each AC medication, AC burden was

determined using the following equation: dose [high, med, low] x days of therapy x ACH
potency [high, med, low]. These classifications as high, medium or low were based on clinical
judgment (by a geriatric pharmacist and researcher) and dosing recommendations for the elderly
obtained from Lexi-Comp®. The resulting values were summed across all AC drugs.

AC

potency was estimated based on published in vivo and in vitro data available in the published
literature, Lexi-Comp and clinical judgment.
There were potential confounding variables including discharge status, race, sex, age, delirium,
and severity score. Discharge status was coded as “yes” = 2 if discharged to a skilled nursing
facility, rehabilitation center, psychiatric center, long-term care hospital, intermediate care
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facility, federal hospital, acute care facility, or hospice/medical facility, otherwise it was coded
as “no” = 1. Race was coded as “White” = 1, “Black” = 2, and “Asian”, “Hispanic”, “North
American Indian/Eskimo” or “other” = 3. Sex was coded as “male” = 1 and “female” = 2.
Delirium was coded as “yes” = 2 and “no” = 1.

The UHC database accounts for severity of

illness and comorbid conditions (CCS) variables using a combination of the Diagnosis-Related
Groups (DRGs) and the UHC Complication Profiler (UCP) (UHC, 2008). Four levels of severity
are defined: as baseline (no substantial CCS), moderate CCS, major CCS, and catastrophic CCS
(surgery).
3.1.2.3 Data Analysis
The prevalence of centrally acting AC drug use was calculated by dividing the number of
patients taking the drugs by the total number of patients in the non-demented group. The
percentage use for each drug was calculated by dividing the number of courses of therapy for
that drug by the total number of courses of therapy for all AC drugs. Average daily dose and
average days of therapy for each of the centrally-acting AC drugs was also calculated.
Stepwise multiple linear regression was used to assess the relationship between LOS and the
independent variables. LOS was log transformed for this analysis. The independent variables
evaluated were standardized scores for age, race, sex, severity score, discharge status, whether or
not delirium was documented, and whether or not the patient received an AC drug. Furthermore,
this technique was also used to determine the relationship between LOS and AC burden in those
patients who received at least one AC medication. This was performed to evaluate whether
higher AC burden is associated with longer LOS in patients without dementia. Again the
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dependent variable was log transformed LOS and the independent variables included were age,
sex, race, severity score, discharge status, delirium diagnosis, and AC burden score.
3.1.3 Results
The results included in this section are preliminary as the study analysis is still continuing.
There were a total of 210,103 inpatients in the dataset without dementia; of this group 37.8% or
79,493 were taking one of the medications listed in Table 4. The patient demographics are
shown in Table 5. The average dose per day, average days of therapy, and frequency of the most
commonly prescribed AC medications are shown in Table 6.
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Table 4: Centrally Acting Drugs with AC Properties

TCA/ TCA Combinations

Antispasmodics

Amitriptyline

Atropine

Amitriptyline/chlordiazepoxide

Belladonna alkaloids

Amitriptyline/perphenazine

Belladonna L-alkaloids

Desipramine

Dicyclomine

Doxepin

Dicyclomine/phenobarbital

Imipramine

Hyoscyamine

Nortriptyline

Scopolamine

Antiparkinson Agents

Urinary Antispasmodics

Benztropine

Oxybutynin

Trihexyphenidyl

Tolterodine

Antipsychotics

Antihistamines

Chlorpromazine

Diphenhydramine

Clozapine

Hydroxyzine

Olanzapine

Promethazine

Promazine
Thioridazine
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Table 5: Patient Demographics

Age (yrs), mean ±SD

75 ±7.3

Females

52.8%

Racial Distribution:
White

69.7%

Black

14.6%

Hispanic

3.7%

Asian

1.6%

Other or unknown

10.4%

Severity Score:
Baseline (no CCs)

23.3%

Moderate CCs

38.6%

Major CCs

27.8%

Catastrophic CCs

9.5%

Unknown

0.7%

Discharge to an institutional setting

20.6%

Documented delirium

1.2%

Median LOS (days)

4.0
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Table 6: Most Commonly used AC Drugs in the Hospitalized Elderly

Drug

Frequency
(%)

Average
dose/day
(mg)

Average
days of
therapy

Diphenhydramine

46

46.5

1.8

Promethazine

22.2

34

1.8

Atropine

9.1

1.6

1.1

Olanzapine

3.8

8.7

4.8

Oxybutynin

3.5

10.2

4.5

For the stepwise regression only 68,697 inpatients from the dataset were included. This was the
total number of inpatients that were taking at least one AC drug and had a complete data set.
The regression found that severity score, discharge status and whether or not the patient received
an AC drug were the most statistically significant predictors of LOS with an r2 of 0.29. The
model accounts for 29% of the variability in the LOS. AC burden was determined to be
statistically significant in relation to length of stay, with only the severity score and discharge
status as more significant, respectively. The r2 value was 0.326 and this demonstrated that the
higher the AC burden for an elderly inpatient, the longer their hospital stays.
3.1.4 Discussion
AC medication administration is common in older adults especially in a hospitalized setting.
Approximately one third of the inpatients without dementia in this study were on an AC
medication. Previous studies have shown a link between the use of diphenhydramine, an AC
medication, and an increase in length of hospital stay as a result of an adverse drug event
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(Agostini et al, 2001). This study demonstrated the same result indicating that intervention
should be evaluated to prevent this outcome.

AC burden is defined by Kay et al as the cumulative effect of taking multiple medications with
AC activity (Kay et al, 2004). There are different ways to determine this burden, one method is
developing an equation as was done in this study. The equation for AC burden was developed
by using the Geriatric Dosage Handbook as a reference in assigning high, medium or low doses
and in determining potency. This approach was used because this is a retrospective study and
blood samples were not available to run a radio receptor assay. The equation method is an
estimate as a true value cannot be determined because each individual’s pharmacokinetics is
different. Therefore, further studies are needed to validate the equation. Other limitations of the
study include the observational and retrospective nature of the study design, which limits the
ability to draw conclusions about causality in the association between AC drug use and hospital
LOS.

In addition, the data was collected from hospital data generated for reimbursement

purposes and not for the specific purposes of this study. This limits the kind of information and
the level of detail available for the study. Also, the potential to cause different AC side effects is
different for each drug depending on blood brain barrier penetration and muscarinic receptor
subtype affinity. Effects were assumed to be additive when they may be synergistic. Drugs with
low potential for AC side effects were not evaluated, but these drugs may contribute to a
cumulative AC effect. Furthermore, delirium appeared to be poorly documented in this dataset,
making it difficult to evaluate as a contributor to hospital LOS.
3.2 Cognitive, Functional and Behavioral Outcomes Associated with Anticholinergic Drug
Use in Alzheimer's Disease Patients Taking Cholinesterase Inhibitors
3.2.1 Background and Significance
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Many different types of medications possess AC properties. These medications can be divided
into two groups, those that are used therapeutically for their AC effects and those that do not
derive their therapeutic benefit by blocking acetylcholine receptors, but have AC side effects.
The first are used to treat clinical disorders frequently comorbid with AD including Parkinson’s
disease and urinary incontinence. Additionally, some may be prescribed to treat the side effects
of cholinesterase inhibitor therapy (Hashimoto et al, 2000; Gill et al, 2005).
A number of studies have reported on the adverse effects associated with AC drugs in general
elderly populations. A few studies have found elderly to be at risk of cognitive impairment even
at low serum AC levels (Mulsant et al, 2003). Impairment of self-care capacity and cognition
have also been found to be associated with high serum AC levels in dementia nursing home
patients (Rovner et al , 1988). AD patients are at risk of additional impairment from AC drug
therapy (Theinhaus et al, 1990). There is little data from clinical studies documenting the
effects of concurrent AC and acetylcholinesterase inhibitor therapy on the cognition, function
and behavior in AD patients. This group is expected to be at even greater risk for adverse
effects of AC drugs due to age and disease-related changes. Surveys of administrative claims
data from different state Medicaid plans have found that patients receiving cholinesterase
inhibitors were also receiving AC drugs with significant central activity during a 3-month
period (Slattum et al, 2001; Carnahan et al, 2006). In a retrospective study of 69 patients with
AD taking donepezil, 16 received concurrent AC medications and experienced a significant
decline in cognitive function over two years compared to patients with no concurrent AC
medications (Lu et al, 2003). A follow-up to this study provides preliminary data that shows a
non-significant decline in physical activities of daily living and instrumental activities of daily
living (Bottiggi et al, 2006).
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The hypothesis that guided this research was that the administration of AC drugs impairs
memory, function, behavior and drug therapy efficacy in AD patients taking cholinesterase
inhibitors. The specific aims for this project included assessing the changes in cognition,
function, and behavior over time in AD patients taking cholinesterase inhibitors and drugs with
AC properties. Additionally, to identify AC medication- and patient-related factors relevant to
cognitive, functional, and behavioral outcomes in this population.
3.2.2 Methods Introduction
This study was modified several times in an attempt to address barriers of feasibility and
recruitment. The original study was an intervention using three local physicians. The physicians
were unable to participate for various reasons, and the study was changed to an observational
design. The initial observational study required a blood draw in order to use SAA to quantify
AC burden. The participants would still have had three visits, but they were required to have
their visits at Medical College of Virginia (MCV) in order for the blood to be drawn.
Participants were unwilling to come to the downtown academic medical center due to the traffic
and nature of a hospital setting. This prompted a change to find another method of calculating
burden without a blood draw to enable patients to be seen at a preferred location such as their
home. The study was changed to use a scale, specifically the Anticholinergic Drug Scale, as a
method of burden quantification. The main reason for the many changes to this study design was
difficulty in patient recruitment.
3.2.2.1 Study Design
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This observational study was conducted in participants with probable AD taking a ChEI in
addition to either a low AC burden or a high AC burden. The total number of participants
needed was 90 with 45 in each of the two AC groups. Selected participants underwent three
assessments of cognition, function and behavior, three months apart in order to determine the
rate of decline in outcome measures. These assessments were performed by a blinded student
investigator and a graduate student.

Demographic data including age, sex, residence, years of

education, current diagnoses, duration of AC drug use, time since AD diagnosis, current AC
dosing regimen, current dosing regimen of acetylcholinesterase inhibitor, indication for AC
medication, other concurrent medications, and perceived effectiveness of AC and cholinesterase
inhibitor medications were obtained on the Patient Intake Form (Appendix A). Furthermore,
demographic data for the caregiver was collected using the Caregiver Intake Form (Appendix B).
Quantification of AC activity resulting from the various AC medications taken by the
participants was determined using the AC Drug Scale (ADS).

An acetylcholinesterase

equivalent dosing chart was used as a means of normalizing cholinesterase inhibitor exposure.
3.2.2.2 Participants

Participants were eligible for inclusion in the study if they had a diagnosis of probably AD based
on medical history, mental status evaluation, clinical examination, or other tests as outlined in
the

Differential

Diagnosis

of

AD

Algorithm

(www.alz.org/Health/Diagnose/procedure.asp).

from

the

Alzheimer's

Association

Diagnosis was confirmed by the referring

physician or the patient’s primary care physician with authorization from the legally authorized
representative. Participants were required to have a Mini-Mental State Examination score of 16
to 24, which corresponds to mild to moderate disease. In addition, participants had to be taking
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a ChEI chronically. All of the currently available ChEIs were included, tacrine, donepezil,
rivastigmine and galantamine. Chronic use of a medication was defined as daily use for greater
than 30 days. Additionally, participants had to be medically stable without evidence of acute
medical or psychiatric illness. Furthermore, they were excluded if they had problems with visual
acuity, hearing or motor disturbances that were severe enough to prevent completion of testing
procedures. Potential participants were also required to have a representative that was able to
provide written informed consent to participate in the study. The participant themselves were
required to provide assent to participate. In addition, a knowledgeable caregiver who was able
to participate in the outcome measurements was required. A knowledgeable caregiver is defined
as the primary person in charge of caring for an individual with Alzheimer’s disease, usually a
family member or a designated health care professional. If the potential participant was residing
in a home or facility they were required to have a caregiver present. Selected participants were
assessed at the location of their choice or at the VCU General Clinical Research Center.

Group 1 participants were taking at least one centrally-acting AC drug chronically. AC drugs
were defined as one of the following: tricyclic antidepressants (amitriptyline, doxepin,
imipramine,

desipramine,

nortriptyline),

sedating

antihistamines

(diphenhydramine,

hydroxyzine, promethazine), antiparkinson’s drugs (benztropine, trihexyphenidyl, biperiden,
procyclidine), urinary antispasmodics (oxybutynin, tolterodine, darifenacin, propantheline,
solifenacin), gastrointestinal antispasmodics (atropine, scopolamine, hyoscyamine, belladonna
alkaloids, dicyclomine), and antipsychotics (chlorpromazine, clozapine, promazine, thioridazine,
olanzapine). Group 2 participants were taking no centrally acting AC drugs from the list above
on a chronic basis.
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Potential participants were recruited through physicians who treat Alzheimer’s patients in the
Greater Richmond area. Physicians were provided with the study protocol and advertisements.
Advertisements were shared with prospective volunteers who contacted the PI if they were
interested in screening for the study. Participants were also recruited through the Alzheimer’s
Association, Greater Richmond Chapter and the Commonwealth of Virginia Alzheimer’s
Commission. The Alzheimer’s Association was provided with advertisements that could be
included in the association newsletter, distributed at support groups and conferences, and other
venues. Also, advertisements were placed in Senior Living magazine and other organizations in
the senior network.

The referring physicians, the Alzheimer’s Association and other

organizations did not provide names or contact information of potential participants directly to
the PI.
The PI or co-investigator conducted the informed consent and assent processes with the
participant and their representative. The participant and their representative received a copy of
the consent form, reviewed it with the PI or co-investigator, and had an opportunity to discuss it
with the PI or co-investigator. Consent was documented in writing.
3.2.2.3 Outcome Measures
Outcome measures were collected during three study visits three months apart with the
participant and their knowledgeable caregiver.

Assessments were made by the student

investigator and a graduate student. Both were fully trained by an experienced psychologist (Dr.
Ayn Welleford, Department of Gerontology, VCU) to administer all of the outcome assessments.
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To avoid potential bias, each participant was de-identified using a number.

Participants were

offered a rest break between measurements.
3.2.2.3.1 Assessments
The specific outcome measures used in this study included the cognitive measures of
Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and the Mini-Mental
State Examination (MMSE) with clock drawing. Functional outcomes included the Physical
Self-Maintenance Scale (PSMS) and behavioral outcomes were assessed using the
Neuropsychiatric Inventory (NPI). The last outcome measured was delirium using the Delirium
Rating Scale-Revised-98.

The ADAS-Cog was the primary assessment of cognition. It is an 11-item test that measures the
disturbances of memory, language, praxis, attention and other cognitive abilities which are often
referred to as the core symptoms of AD with a score ranging from 0 to 70 with higher scores
corresponding to more impairment.

This test was used in the anti-dementia trials and is

considered the gold-standard. Cross-sectional and longitudinal studies have shown that the total
score on the ADAS-cog correlates with disease severity (Sevigny et al, 2010). Moreover, studies
have shown that the ADAS-cog has high sensitivity and specificity for evaluating disease
severity (Pera-Casanova, 1997).
The second cognitive assessment tool was the MMSE with clock drawing, which was performed
to facilitate comparison of the results with other studies. This test is a simple and brief standard
mental status exam routinely used to measure a person’s basic cognitive skills. This 11-item
instrument evaluates several cognitive domains such as short-term memory, long-term memory,
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orientation, registration, attention, visual construction skills and language. Scores range from 0 to
30, with higher scores corresponding to less impairment. The MMSE has sensitivity (87%) and
specificity (82%) in the identification of dementia (Rosselli et al, 2006).

The PSMS, the functional instrument, is a brief assessment of the activities of daily living,
specifically the ability to perform self-care, self-maintenance and physical activities. It is a sixitem scale that rates self-care ability in toileting, feeding, dressing, personal hygiene and
grooming, locomotion (physical ambulation), and bathing.
provided by caregivers.

It is based on the information

For each activity, the patient is rated from 1 (independence) to 5

(dependence), hence higher scores are indicative of more impairment (Lawton et al, 1969).
Behavior was assessed using the NPI, a tool that evaluates 10 disturbances associated with
dementia.

These include delusions, hallucinations, dysphoria, anxiety, agitation/aggression,

euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. There are two
additional behaviors that are assessed including night-time behavior disturbances, and appetite
and eating abnormalities. The NPI measures both frequency and severity of each behavior. This
assessment also uses caregiver input to assess these disturbances.

A high score on this

instrument is associated with greater impairment (Cummings et al, 1994).
The last assessment used in this study was the Delirium Rating Scale-Revised-98, a tool to
evaluate delirium in the dementia participant. This is a validated, 16-item clinician-rated scale
with 13 severity items and 3 diagnostic items, maximum total scale score of 46 points (includes
the three diagnostic items) and a maximum severity score of 39 points (Trzepacz et al, 2001). It
is not uncommon for older adults to suffer from drug-induced delirium with AC medications,
especially in those with dementia (Gareri et al, 2007).
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3.2.2.3.2 AC Burden Quantification
The ADS was used to calculate AC burden in the participant at each visit. This was done by
obtaining a full list of medications from the participant. The ADS quantifies the AC potency of
each medication based on ratings. Each medication, both chronic and as needed, was rated on a
level of 0 to 3. Level 0 medications have no known AC properties; level 1 medications are
potentially AC based on receptor binding studies; level 2 medications have been shown to cause
AC adverse events at excessive doses; and level 3 medications are known to be markedly AC. A
list of medications that are rated as 0 to 3 is provided in Appendix B (Carnahan et al, 2006). The
ratings were then added together to determine the ADS total score. If a medication is used as
both a scheduled and as needed medication then its rating is added twice.
3.2.2.3.3 ChEI Categorization
A ChEI dosing table was used to categorize the dose as initial, middle or maximal since the
medications have been shown to have similar efficacy (Wilkinson et al, 2002; Liston et al 2004).
The initial dose of donepezil is 5 mg and the maximal dose is 10 mg. The initial dose of
rivastigmine is 3 mg, the middle dose is 6 mg to 9 mg and the maximal dose is 12 mg. The initial
dose of the rivastigmine patch is 9 mg and the maximal is 18 mg.

The initial dose of

galantamine immediate release and extended release is 8 mg, the middle dose is 16 mg and the
maximal dose is 24 mg.

3.2.2.4 Statistical Analysis
3.2.2.4.1 Sample Size
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The calculation of the number of required participants for this study was based on a study
conducted in non-demented and probable Alzheimer’s patients where SAA was correlated with
cognitive performance with r = 0.29 (Theinhaus et al, 1990). The sample size necessary to detect
a similar correlation in our study (α = 0.05, β = 0.20, for a one-sided test) is 67. A second basis
for the sample size was a t-test comparison of low and high AC burden patients. It was assumed
that patients with mild to moderate AD with high AC burden will behave as patients receiving a
placebo rather than a ChEI. Data on change from baseline in ADAS-cog score for placebo
treated and optimally treated patients can be used to estimate sample size. In a study of patients
with mild to moderated AD, the weighted mean difference in change in ADAS-cog score over
six months for placebo and donepezil treated patients was 2.92 with equal SD of 5.5 (Birks J,
2006). The sample size necessary to detect a similar difference (α = 0.05, β = 0.20, for a onesided test) is 45 per group.
3.2.2.4.2 Analysis Plan
The change over 6 months for each clinical outcome was to be compared for Groups 1 and 2
using a one-sided t-test (α = 0.05). If assumptions of the t-test were not met, data transformation
and alternative approaches would be explored.

This analysis assumes that participants would

remain in the high or low burden group throughout the six month study period. After the first 20
participants completed the study, the validity of this assumption was to be assessed. Based on
the results of the first 20 participants, the study analysis plan might have been adjusted.
Additionally, in the case that an alternative plan was needed the data collected at the 3-month
assessment could have been used in the analysis.
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The relationship between each clinical outcome and anticholinergic activity at each visit was to
be evaluated using multiple regression. Demographic variables (patient and therapy-related
factors) and cholinesterase inhibitor dose category would be included as dependent variables in
each analysis. Statistical analyses were to be performed using SPSS Version 16.0 for Windows.
3.2.3 Results
The study was closed in the Spring of 2010 due to low enrollment. During the two years that the
study was open there were three participants that completed all three study visits. There were
two more participants who were unable to maintain the minimum MMSE requirement at the first
visit. Subject 4 was unable to finish the assessments due to aggression and agitation. It was
determined that she would be unable to continue the study due to the progression of her disease.
Subject 5 was cooperative, but had a MMSE score of 12/30 following the first meeting. This fell
below the 16/30 minimum requirement.
Of the three participants that completed the study, one had high AC burden and the other two fell
into the low AC burden group.

The demographics are shown in Table 7.

For all three

participants there was no change in the AC medications or in the ChEIs and NMDA receptor
antagonists that they were taking over the six month time period. All three participants were
taking donepezil and two of the three were taking memantine.

The average age of the

participants was 71.7 ± 12.0. As shown in Appendix A, there were several domains collected on
each participant, but the questionnaire was incomplete for some of the participants. Hence only
the variables listed in Table 7 were complete for all participants.
Table 7: Demographics
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Subject 1 Subject 2 Subject 3
Age

84

71

60

Sex

Female

Male

Male

Status

Married

Married* Married

Ethnicity

White

Black

White

Residence

ALF

Home

Home

Education

16

12

20

Smoking

No

No

No

Marital

* Widowed after 2nd visit
The summary of the outcomes for each participant is located in Table 8. As shown in Table 8,
Participant 1 has the highest ADS score that corresponds to the lowest MMSE and ADAS-cog
scores. Participant 1 was taking solifenacin which is known to be markedly AC based on SAA
studies. The NPI scores did not conform to the trend that was seen between ADS scores and
cognition as well as function. Regression analyses were not performed due to the small sample
size.
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Table 8: Summary of Outcome Measures

Visit 1

Visit 2

Visit 3

Average ± Std Dev

Subject 1

Subject 2

Subject 3

Subject 1

Subject 2

Subject 3

Subject 1

Subject 2

Subject 3

Subject 1

Subject 2

Subject 3

ADAS-cog

29.0

18.0

25.0

26.0

16.0

26.0

41.0

20.0

30.0

32.0 ± 7.93

18.0 ± 2.00

27.0 ± 2.65

MMSE

17.0

24.0

20.0

19.0

24.0

20.0

17.0

24.0

21.0

17.7 ± 1.15

24.0

20.3 ± 0.58

Delirium

13.0

6.0

9.0

15.0

7.0

11.0

14.0

5.0

13.0

14.0 ± 1.00

6.0 ± 1.00

11.0 ± 2.00

NPI

3.0

11.0

38.0

3.0

10.0

29.0

3.0

0.0

28.0

3.0

7.0 ± 6.08

31.7 ± 5.51

Caregiver
Occupational
Distress
(NPI)

2.0

9.0

14.0

2.0

5.0

13.0

2.0

0.0

8.0

2.0

4.7 ± 4.51

11.7 ± 3.21

PSMS

11.0

9.0

6.0

13.0

9.0

8.0

13.0

6.0

8.0

12.3 ± 1.15

8.0 ± 1.73

7.3 ± 1.15

ADS

3.0

0.0

0.0

3.0

0.0

0.0

3.0

0.0

0.0

3.0

0.0

0.0

ChE

Maximal

Initial

Maximal

Maximal

Initial

Maximal

Maximal

Initial

Maximal

Maximal

Initial

Maximal
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3.2.4 Discussion
The lack of participants accounted for the premature termination of the study. Much time was
spent on advertising to caregivers and healthcare workers to no avail. The three participants
were recruited by means of different avenues. Participant 1’s caregiver contacted the PI about the
study, while Participant 2 was recruited by their physician and Participant 3 by the local
Alzheimer’s Association chapter.

There were barriers that were faced in recruitment of

participants. Many of the barriers were legal in nature with the nursing homes, assisted living
facilities, and adult day centers. These facilities required approval from the power of attorneys
(POAs) or family members in order for the patients or residents participate. In addition, many of
these facilities were not willing to send a letter with the advertisement to the families and POAs.
For the few adult day centers interested in participating, there was either a lack of interest among
the families/POAs or the patient did not meet the requirements to participate. One assisted living
facility that also had an independent living section, allowed for the advertisement to be posted in
the pharmacy. This was the advertisement that Participant 1’s husband saw. As discussed
previously, spousal and family support was a significant barrier to participating in research
studies. The study by Marcantonio et al. in 2008 found that approximately 55% of potential
participants indicated that they would decline if their spouse was not interested or did not
approve of the research (Marcantonio et al, 2008).
Another barrier that was faced was associated with physician support. Physicians from the
Alzheimer’s Association referral list of doctors who treat AD patients were contacted and asked
to facilitate patient recruitment. Many physicians chose not to participate in either providing a
flyer to the possible participant or posting the flyer in their office or practice site. This may be
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due to the perceived additional work that is involved in assisting to recruit patients. Additional
barriers may have been bias towards research or lack of belief in the importance of the research
question (Sullivan-Bolyai et al, 2007).
One additional barrier may have been perceived benefit. AD is an irreversible disease that leads
to significant loss of quality of life. This study was not a treatment study and therefore may have
been considered a less worthwhile project to participate in.
There was a great deal of variability between the three participants that may have contributed to
their cognitive, behavioral and functional scores. Participant 1’s caregiver was her husband yet
did not live with her in her apartment unlike the other two. Furthermore, she had a twin who had
passed away from AD.

Participant 2’s third visit NPI and PSMS scores were based on

information provided by the daughter who did not live with him. His wife had passed away not
long before the third visit. This is likely why the NPI and the Caregiver Occupational Distress
scores were significantly less than the previous visits. Participant 3’s caregiver was the only one
who worked outside the home and had younger children.

This explains in part the significantly

higher NPI and Caregiver Occupational Distress scores. These factors make any generalizations
impossible as does the small sample size.
The student investigator was present at all visits and performed all cognitive and delirium
assessments. The additional graduate student was present at all 3 of Participant 1 and 2’s visits.
Also, she completed the PSMS and NPI with the caregivers for these two subjects. Therefore,
inter-rater reliability was high.
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In conclusion, this study had the potential to provide valuable evidence as to whether AC burden
has a negative effect on cognition, function, and behavior in AD patients. Due to the multiple
barriers associated with recruiting participants this study was terminated. Further research in this
area is necessary as the pharmacological potential for negative consequences of AC burden in
AD may not translate to clinical adverse events.

Moreover, further research is needed in

overcoming barriers associated with AD patient and caregiver participation. This will provide
for greater participation in important studies that may improve the quality of life patients and
their caregivers.
3.3 Chapter Summary
This chapter described two preliminary research studies. The first is still ongoing, but the initial
findings support other research with respect to the prevalence of 33% and the increased LOS
associated with use of AC medications. As shown in Table 2 from Chapter 1, within the last 30
years the prevalence has ranged from as low as 6% to as high as 80%.

The majority of the

studies found that the range was about 20%-30%. Additionally, the study by Agostini et al,
found that length of stay was increased with the use of diphenhydramine. The results from the
second study are inconclusive with so few participants. With growing evidence for the high
prevalence of AC medications and the negative effects associated with their use in older adults, it
is imperative that more research be conducted in dementia patients using these medications. The
second study had the potential to evaluate the use of AC medications on dementia patients, but
due to recruitment barriers, this was not completed. The next option is to perform a retrospective
analysis of dementia patients, which is the basis for the study discussed in the next chapters.
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Chapter 4
Methods
4.0 Chapter Introduction
This chapter describes the methods for a retrospective, longitudinal study that was conducted
using data from patient charts for dementia patients receiving care at Piedmont Geriatric
Hospital. This study was derived from the prospective preliminary study discussed in the
previous chapter. Hence the same outcomes of function, behavior and cognition were evaluated,
but through different assessments. Additionally, the objective of evaluating the association
between AC burden and functional, behavioral and cognitive outcomes was the same as the
preliminary study. The patients were identified by the hospital and then charts were reviewed to
obtain the demographic, pharmacy and outcome information. This data was compiled and then
statistical analysis was preformed to identify any associations between the outcomes and AC
burden. The process is described in detail below.
4.1 Effect of Anticholinergic Burden on Functional Outcomes in Patients with Dementia
4.1.1 Study Design
The study was a retrospective observational study of moderate to severe dementia patients at a
state geriatric facility. Both the VCU Institutional Review Board (IRB) and Piedmont Geriatric
Hospital (PGH) IRB approved the study protocol.
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PGH is Virginia’s only state facility exclusively for older adults aged 65 and over with mental
illness. It is a 135-bed hospital located in rural Burkeville, VA. Typically only about 122 to 128
beds are filled at any given time. The patient length of stay varies from a few days to several
years depending on the severity of the patient’s condition (Piedmont Geriatric Hospital, 2010).
The hospital requires that authorization be received to use any chart information, including nonpersonal health information (PHI). A letter was used as informed consent and sent out to the
family and representatives for the patients’ who were still living. This letter is included in
Appendix C. The families and representatives were given two weeks to decline interest. A nonresponse was deemed as an agreement to be included in the study.
Charts dated from 2000 to the present were reviewed to obtain the monthly nursing reports. Data
from the reports were recorded for the first six months and the last six months of the hospital stay
for every individual. Data from the in-between months were collected quarterly. As an example,
subject “A” was a patient at PGH from January 2002 through December 2003, therefore January
2002 to June 2002 was recorded monthly, followed by September 2002, December 2003, March
2003 and then monthly from July 2003 to December 2003. Therefore a total of 15 time points
were recorded for subject “A.” When a patient is admitted to PGH it is because they present a
danger to themselves or others, require continuous care, or have needs that cannot be met
properly by a nursing facility or assisted living facility (Piedmont Geriatric Hospital, 2010).
Hence they usually require stabilization upon admission and this is typically accomplished by
changes in the medication regimen. Therefore the first six months were collected in order to
account for any changes that the alteration in medications may have on their function, behavior
and cognition. The last six months were collected to measure the changes in progression at the
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end of the disease for those that had deceased at PGH and the progression to stabilization for
those that were discharged.
In addition to the nursing report, demographic information was collected from the physician,
social worker and psychologist notes. The prescription history for every month that the patient’s
nursing report was recorded was noted. The IRB approved collection form is included in
Appendix 4. This form does not include any PHI and therefore this study was approved as an
exempt IRB protocol.
4.1.2 Participants
Patients were selected if they had a diagnosis of dementia and had been at PGH within the last
six years. Six years was chosen because the pharmacy only keeps records for six years. These
patients were identified by the health information management (HIM) specialist, Peggy Vaughn,
who worked with the billing department to identify potential subjects. There were 56 patients
that were deceased at the time of the identification and then additional 37 patients who had to be
contacted as they were alive and no longer at PGH. These 37 patients had a letter sent to their
family/representative. There were 10 patients whose family or representative declined their
participation or the letter did not reach them. Therefore there were a total of 83 patients included
in this study.
Initially only patients with a diagnosis of AD were to be included. After the billing records were
checked there were only 28 patients with a primary diagnosis of dementia. The computer billing
program is unable to identify patients by their secondary diagnosis. Therefore if a patient’s
primary diagnosis is Parkinson’s disease with a secondary diagnosis of AD or dementia, then
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they will not be added to the report. Based on this information the diagnosis of interest was
widened to all dementia to increase the number of potential participants in the study.
Another method of increasing participants in the study that was attempted was to use records
from the other state facilities that had geriatric patients with dementia. The issue that arose was
the measures of function, cognition and behavior varied across all of the facilities and there was
not a clear method of standardizing the assessments between hospitals. While PGH used the
Functional Independence Measure Scale (FIMS), another facility, Catawba Hospital relied upon
nursing notes rather than a specific assessment tool for the measurement of function. Therefore
all of the participants in this study were from PGH.
4.1.3 Data Collection
The student investigator (S. Dharia) went to PGH on several occasions to obtain the data. The
sources of patient information were the medical chart and the pharmacy database, if needed, for
prescription history. In terms of prescription history, any prescriptions prior to 2004 had to be
collected from the chart only. Much of the pharmacy medication record was already in the chart.
The charts used were located in the medical records room, on microfiche, in the overflow chart
room, or on the units. For patients who were deceased or discharged the first two locations were
where the majority of information was collected. The second two locations were for patients that
were still at PGH or that were just recently discharged. The list of patients identified by HIM
was used to find the charts. As mentioned above, the majority of information was collected from
the healthcare notes. The nursing report was located in the middle section of the chart along with
the daily medical notes. The pharmacy monthly prescription information was found at the
beginning of the chart. The physician, social worker and psychologist notes were all found in the
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first chart that the patient had. The majority of the patients had more than one chart as only six
months was allocated to each one. The records from 2000 to 2010 were reviewed for patient and
disease specific information. Data prior to this date was not collected as the specific outcome
assessments were not in use prior to 2000.
Many of the patients had multiple admissions during the course of their disease progression,
therefore only their first admission was included. This was done to ensure that the rate of
progression was captured with as few external influences and to limit variability on the patients’
progression through the disease. Additionally, as indicated above when a patient is admitted to
PGH, stabilization of the patient’s condition is required and therefore each admission would alter
the rate of progression of the disease.
As mentioned above in the study design section, data from the first six months and last six
months, if available, were collected for each patient’s stay. Additionally, for the months in
between, data was collected quarterly.
The specific data collected included age, sex, marital status, ethnicity, length of stay, number of
admissions, residence prior to admission, education, smoking and alcohol use status, conditions
at first admission, year of dementia diagnosis, and ChEIs and memantine use. The ChEIs and
memantine use was collected from the charts, under the pharmacy prescriptions and the
physician notes from admission that documented past medication history.

This data was

collected as past research has shown that these factors may influence the progression or the
improvement of dementia (Alzheimer’s Association 2010)( Birks J, 2006). As mentioned above,
PHI including name, date of birth, admission and discharge dates were not recorded to protect
patient privacy. This specific information was needed to identify the patient charts, collect the
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data and match the pharmacy data from the chart with the pharmacy database. The student
investigator (S. Dharia) and on one occasion for one patient a gerontology student recorded the
information. These two students underwent required HIPPA training prior to collecting or
recording any information.
The coding scheme for the variables is located in Table 9.

All other variables remained

continuous.
Table 9: Variable Coding Scheme
Variable
Sex

Coding Scheme
“male” = 0; “female” = 1
“married” = 1
“single” = 2
“widowed” = 3
“divorced” = 4
“separated” = 5
“unknown” = 9
“White” = 1
“Black” = 2
“Hispanic” = 3
“Asian/Pacific Islander” = 4
“Native American” = 5
“unknown” = 9
“home with no assistance” = 1
“home with assistance” = 2
“assisted living facility” = 3
“skilled nursing facility” = 4
“unknown” = 9
“<K-5” = 1
“K-5” = 2
“6-8” = 3
“9-12” = 4
“>12+” = 5
“unknown” = 9
“no” = 0
“yes” = 1
“unknown” = 9
“no” = 0
“yes” = 1

Marital Status

Ethnicity/Race

Residence Prior to Admission

Education

Smoking
Alcohol
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Variable

Coding Scheme
“unknown” = 9
“donepezil” = 1
“rivastigmine” = 2
“galantamine” = 3
“memantine” = 4
“unknown” = 9
“yes” = 1
“no” = 0
“unknown” = 9
“change” = 1
“no change” = 2
“change” = 1
“no change” = 2

AD Medications

Conditions Present on Admission
Change in Cognition
Change in Behavior

As mentioned above, monthly medication lists were collected from the chart and the pharmacy
dispensing database.

The pharmacy dispensing database was only searched when the

information was not available in the chart. If there was a disagreement between the two sources
of prescription information, the physician notes and the nurses’ medication log were checked and
verified. Specifically, all medications and their dosages for each patient were collected. The
medication information was collected for every month that was recorded. As a clarification,
drugs for the first six months, last six months and then quarterly in between were collected. This
information was used to determine the AC burden score using the ADS (Carnahan et al, 2006).
The ADS, as mentioned in the introduction, is a non-invasive method of AC burden
quantification. This method assigns ratings of 0 to 3 for a list of medications. This list is in
Appendix B. The ratings are defined as follows, level 0 = no known AC properties; level 1 =
potentially AC as evidenced by receptor binding studies; level 2 = AC adverse events sometimes
noted, usually at excessive doses; and level 3 = markedly AC. The ratings were then added
together to determine the ADS total score. If a medication was used as both a scheduled and as
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needed medication then its rating was added twice.

For instance, if a patient was taking

tolterodine (ADS = 3) for urinary incontinence, alprazolam (ADS = 1) for anxiety as needed and
alendronate (ADS = 0) for osteoporosis, the total ADS score for this patient would be a 4. This
method was chosen for its use in a retrospective study using medical records. The DBI would
have been another option, but it only considers dose and not the level of AC activity as the ADS
does. The ideal scale would have taken both into consideration.
4.1.4 Assessments
The clinical outcome of interest for the primary study objective was the change in function over
time. This objective was to assess the function in dementia patients with varying AC burden. To
accomplish this, functional information was collected from the chart, specifically from the
Functional Independence Measure Scale (FIMS) that is part of the monthly nursing report. This
scale was originally developed to assess functional gains in patients undergoing rehabilitation for
a stroke.

Since then it has become widely used in rehabilitation facilities and for the

measurement of activities of daily living (ADLs) in dementia patients (Cotter et al, 2002). The
FIMS is also used at Veterans Administration hospitals and in continuing care centers. This
measurement assesses how independent a person is on a scale of 1 to 7. Where 1 = complete
dependence and 7 = complete independence. The original scale assesses the areas of self-care
(grooming, dressing, eating, etc.), sphincter control, mobility, locomotion, communication and
social cognition (Oczkowski et al, 1993; Amundson et al, 2010). As a measure for ADLs in
dementia patients the scale was modified to all areas but the communication and social cognition
portions (Cotter et al, 2002). A study by Cotter et al showed that this tool is as effective in
measuring ADLs as caregiver reports (Cotter et al, 2002). This tool would decrease the amount
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of time spent writing a monthly note about the patient’s ADL status, which was method of
assessment prior to 2000 at PGH. In addition, this is a standardized method of assessing function
when there are several nurses involved in the patients’ care. As mentioned above the FIMS was
first used in 2000 and then through the years it was further modified. The original modified
scale used at PGH in 2000 measured 13 areas including eating, grooming, bathing, dressing
upper, dressing lower, toileting, bladder management, bowel management, bed to chair or
wheelchair transfer, ability to transfer to toilet, tub/shower, walking or use of wheelchair, and the
ability to use the stairs. The newer modified version that PGH started using in 2007 only had 9
items and did not include the transfer from bed to chair/wheelchair, transfer to the toilet,
tub/shower transfer or use of stairs. It not known why a modified version was used or why it was
further shortened in 2007.

It may have been that communication and social cognition are

impaired in the majority of patients who are admitted to PGH. Additionally, patients never take
the stairs at PGH and many of the patients are in wheelchairs or require assistance to the toilet or
shower. As the FIMS is part of the nursing report, the nursing staff fills it out. The extent of the
training given to the nurses on the FIMS is unknown.
The secondary objectives were to assess the cognition and behavior in dementia patients with
varying AC burdens.

Cognitive status and behavioral status were evaluated using the Monthly

Nursing Recovery Summary attached to the FIMS score.

The notes provided nursing

observations of behavior and cognition collected for each particular month. The first page of the
nursing report was dedicated for the documentation of behavior and cognition. These notes were
then interpreted only by the student investigator (S. Dharia) as a change or no change from the
previous month or report. Change referred to worsening behavior or cognition. In many reports,
there were notes of “increased hitting” or “more confusion,” which were then both coded as a
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change. In other reports, the notes would say “1 instance of hitting” and then the next month
would say the same thing. This was translated as no change from the month before. A positive
change was rare, but if it did occur it was minor and categorized as no change. If the positive
change was significant then a notation would have been made on the collection form that
behavior or cognition had improved from the month or quarter before. There were no instances
of significant positive change for any of the patients.
4.1.5 Statistical Analysis
Descriptive statistics were used to describe the data. Also, regression analysis was used to
explore the relationship between the outcomes and ADS scores. Data from the collection forms
was complied into an Excel spreadsheet. Excel 2007 and SPSS 18.0 were used to calculate
descriptive statistics including mean (median and range), percentages and total counts.
Additionally, the FIMS scores were plotted to assess the distribution and assess for normality.
The distribution was found to be a more s-shaped distribution. Data transformations were
performed to obtain a normal distribution. The distributions were evaluated using the ShapiroWilk test, the Q-Q plots, the histograms, and the box-plots. The distribution was kept at normal
and the link function as identity. These are the pre-set model types for linear scale responses.
For the cognitive and behavioral outcomes the model type was selected as binary logistic. This
was because the data was “yes/no” responses to change.
A sample size calculation was performed using the following equation:
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Where

is the z-score for the alpha level, which is 0.05 for a two-tailed test, and therefore

0.025 for this situation. The z β is the z-score for the beta level or Type 2 error and 0.80 for 80%
power. The σ is the estimate of the standard deviation which is equivalent to the FIMS minimum
score subtracted from the maximum score divided by six. The ρ is the within-subject variance
which is estimated to be zero in ideal cases. δ2 refers to the minimum clinically important effect
size. The literature was searched to find this value, two articles relating to dementia with the
recorded effect sizes were identified. They were both for cognitive outcomes in dementia and
not functional outcomes (Colcombe et al, 2003; Oken et al, 1998). Both articles found effect
sizes to be an average of 0.45. This value was used in this equation. The m is the number of
repeated of measures which in this case was the average of the number of observations for the
patients. Using this equation it was determined that to see a difference a sample size of 435.47
or 436 patients was needed. Typically sample size calculations are used in experimental studies
and not retrospective, observational ones. In this study, the sample size was much smaller than
436 participants and as mentioned in section 4.1.2 reaching this number was not achievable.
The relationship between outcomes of interest and the other variables were modeled using a
generalized estimating equation approach (GEE).

GEE was chosen over other statistical

methods such as random effects as it makes fewer assumptions and therefore has a lower risk of
bias. It is consistent even if the correlation structure is misspecified (Twisk, 2003). Also it is an
appropriate method to use when the data is longitudinal in nature as in this study.
The data was reviewed and the participants with only one time point were removed as a change
in function, cognition and behavior over time were the objectives of interest. Following this, a
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correlation structure was selected based on a within subject correlation structure table. This table
is based on the first six month time points and is displayed below as Table 10.
Table 10: Within Subject Correlation Structure

Y1
Y2
Y3
Y4
Y5
Y6

Y1
-

Y2
Y3
Y4
Y5
Y6
0.014
0.121
0.165
0.207
0.253
0.109
0.138
0.179
0.226
0.027
0.067
0.115
0.042
0.091
0.048
-

There are five correlation structures that could have been selected including independent,
exchangeable, m-dependent, autoregressive and unstructured. The independent structure was
excluded as the correlations between measurements cannot be assumed to be zero. Furthermore,
unstructured, which assumes that all of the correlations are different, was excluded due to
computational challenges associated with a small sample size resulting in the estimation
algorithm failing to converge. The autoregressive structure was initially eliminated as it works
best with equally spaced time points. For this analysis, time was collected quarterly with each
of the first six months and last six months collected as well. The data was then changed to
accommodate this equally spaced requirement by using the first and the fourth month to run the
analysis. Exchangeable assumes that the correlations between measurements are equal (Twisk,
2003). For this data that is not the case, but it may be an appropriate structure to use. Mdependent assumes that correlations one measurement apart are equal, two measurements apart
are equal and so forth. This is a more appropriate structure, but it is less desirable for the data as
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it is a relatively small set and m-dependent requires estimating additional parameters (Twisk,
2003).
The data was analyzed using these three specific structures, autoregressive, exchangeable, and
m-dependent, for comparison purposes. The dataset minus those with only one time point was
used to compare the exchangeable and the m-dependent structures only.
Additionally, a second modified dataset was created based on the patients who were at PGH for a
minimum of six months. This second dataset was used as the correlation structure was based on
these results. Exchangeable and m-dependent structures were used on this dataset.
A third dataset was created to run an autoregressive correlation structure. The months in this
dataset were quarterly. Therefore for the first six months, months 2, 3, 5, and 6 were removed
and then the same was done for the last six months.
Another analysis was run using the significant variables from the first analysis for all of the
correlation structures and their corresponding data sets. Additionally, the insignificant variables
that may have influenced them were included. The insignificant variables that may have caused
a change of 20% or more in the coefficients of the significant variables were the ones that were
included in this second analysis. This assesses for potential confounding in the variables. If
insignificant variables cause a 20% or greater change in the estimates then it is said to be a
potential confounder.
There were a total of 10 outputs for the different models listed above.

The use of three

correlation structures was only used for the assessment of the functional outcome. The cognitive
and behavioral outcomes were evaluated using GEE regression for categorical data and used the
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exchangeable structure as they are coded yes/no responses. There are a total of four outputs for
both of these outcomes.
A goodness of fit test (QIC) was performed using SPSS and was used to evaluate how well the
model fits the observations. This was then useful in determining which of the correlation
structures was more appropriate. A Huber-White sandwich estimator was used as a way to
ensure that the variances were robust. Specifically, robust variances are important as they
provide accurate assessments of the sample-to-sample variability of the parameter estimates even
if the model is misspecified (Norusis, 2008).
For the test of model effects, Type III, was selected for all analysis as it does not depend on the
entry order of the variables like Type I does. Test Type III is typically preferred unless order of
the variables is important, which in this case it is not.
There were several independent variables evaluated for the three outcomes including age, sex,
marital status, ethnicity, length of stay, number of admissions, residence prior to admission,
education, smoking and alcohol use status, year of dementia diagnosis, functional comorbidity
index, constipation, and ChEI and memantine use.
The functional comorbidity index (FCI) is a tool that predicts function for patients who have
comorbid diseases such as diabetes or COPD. The FCI was more effective in evaluating an
association to physical function compared with the Charlson Comorbidity and the KaplanFerinstein indices (Groll et al, 2005). It includes most common diagnosis, but as it is based on
secondary data, there may be others that should have been included. Overall the FCI is a useful
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tool and the only general population-based functional index. This tool assigns “1” if a person
has one of the 18 diseases and “0” if they do not (Groll et al, 2005).
There was one select condition that may be considered a side effect of the use of AC medications
that was included in this analysis, constipation. The other disease states recorded were not
included in the analysis as only those in the FCI have been shown to have an association with
functional outcomes. These conditions were still included in the descriptive statistics.
The α-level was set at 0.05. Statistical analyses were performed using SPSS Version 18.0 for
Windows.
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Chapter 5
Results
5.1 Results
5.1.1 Descriptive Results
There were a total of 83 subjects included in this study with a median age of 77 years and a range
of 65 to 94 years at admission. Table 11 displays the demographics of the patients. The majority
of the subjects were either married or widowed white males that were living in a nursing home or
hospital prior to being admitted to PGH. Furthermore, the majority graduated high school or had
some college. The participants were at PGH for a median of 536 days, with a range of 13 to
2973 days.
While all of the patients had a diagnosis of dementia, only 33.7% were taking a cognitiveenhancing medication. Of those 36 patients taking (or did so previously) a ChEI or memantine,
the majority were taking donepezil as their first or second cognitive-enhancing medication.
There were eight participants taking two cognitive-enhancing treatments during their stay a
PGH. None of the patients took galantamine as their second medication. The median ADS score
was 3.0 with the majority of patients having ADS scores ranging from 1 to 3. There were several
AC medications that this sample received, divalproex, olanzapine, lorazepam, sertraline, and
furosemide were the most commonly used.
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Table 11: Demographics

Age (Years) at Admission

Mean ± SD

Average

78 ± 6

Sex

% (N)

Female

32.5% (27)

Male

67.5% (56)

Race/ Ethnicity

% (N)

White

63.9% (53)

Black

32.5% (27)

Hispanic

1.2% (1)

Asian/Pacific Islander

1.2% (1)

American Indian

1.2% (1)

Marital Status

% (N)

Married

34.9% (29)

Single

8.4% (7)

Widowed

31.3% (26)

Divorced

20.5% (17)

Separated

1.2% (1)

Unknown

3.6% (3)

Highest Education Achieved (Years)

% (N)

<K-5

10.8% (9)
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K-5

2.4% (2)

6-8

21.7% (18)

9-12

36.1% (30)

>12+

24.1% (20)

Unknown

4.8% (4)

Residence Prior to Admission

% (N)

Home w/ no Assistance

15.7% (13)

Home w/ Assistance

19.3% (16)

ALF

8.4% (7)

SNF

55.4% (46)

Unknown

1.2% (1)

LOS
Range (days)*

13-2973

Mean (days)*

769 ± 756

Median (days)*

536

Mean (months)^

19.6 ± 20.1

* number of days patient was in hospital during 1st admission
^ number of months from first FIMS (no earlier than 2000) to last FIMS score
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As shown in Table 12, the FIMS score had a wide range with a median of 14. None of the
patients had a maximal FIMS score of 81, the highest was 65. Due to this wide range of FIMS
score, a test of normality was performed. The Q-Q plot for the non-transformed data is located
in Figure 1. The Shapiro-Wilks test was used to assess for normality and it was significant with
a p-value <0.01 indicating that the data were not normally distributed. Several methods were
used to transform the data to obtain normality. None of the methods produced a non-significant
Shapiro-Wilk’s test. The Q-Q plots were assessed and the natural logarithmic transformation of
the data produced a normal distribution visually compared to the other transformations (Figure
2). Additionally, the histogram and box-plots were assessed to determine the most appropriate
data transformation.

The plots and the histogram using the logarithmic transformation were

much more normal visually than the other transformations and the original scores. Normality is
not an assumption of GEE and research using GEE has shown to produce robust results with
skewed data (Lee et al, 2007). Therefore the logarithmic distribution was used in the analysis.
Table 12: AD Treatment and Outcomes
AD Treatment
Yes
Previous
First AD Medication*
donepezil
rivastigmine
galantamine
memantine
Second AD Medication**
donepezil
rivastigmine
memantine
ADS
Range

% (N)
33.7% (28)
9.6% (8)
% (N)
50.0% (18)
13.9% (5)
11.1% (4)
25% (9)
% (N)
62.5% (5)
25.0% (2)
12.5% (1)
0.0-11
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Mean ± Std Dev
FIMS Score
Range
Mean ± Std Dev
Change in Cognition^
Yes
Change in Behavior^
Yes

3.0 ± 2.1
8.0 - 65.0
19.1 ± 13.0
% (N)
40.9% (464)
% (N)
69.3% (786)

* Total n = 36
** Total n = 8
^ Total n = 1135, the number of total observations

Figure 1: Distribution of FIMS Scores
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Figure 2: Distribution of the Natural Log of the FIMS Scores

Table 13 displays the health related demographics. The majority of patients were non-smokers
and about half either drank or were previous drinkers. There were some patients that had
developed dementia due to heavy alcohol use.

The most common disease conditions at

admission were hypertension and other cardiovascular disorders, such as myocardial infarction
(MI), stroke, congestive heart failure (CHF), coronary artery disease (CAD), and peripheral
vascular disease (PVD). There were some conditions listed on the collection form that were not
present in this patient population including certain gastrointestinal (GI) conditions such as
diarrhea and nausea/vomiting. The average FCI was 2.2 with a range of 0 to 22. The FCI
accounted for several disease states including, arthritis, osteoporosis, asthma, chronic obstructive
pulmonary disease (COPD), angina, CHF, MI, Parkinson’s disease (PD), stroke, PVD, diabetes,
upper gastrointestinal diseases, depression, anxiety, visual impairment, hearing impairment,
degenerative disc disease including osteoporosis, and obesity.
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Table 13: Health Related Demographics
Smoking
No
Previous
Unknown
Alcohol
No
Previous
Unknown
Disease States on Admission
HTN
Other CV
Constipation
High Cholesterol
Diabetes
Thyroid Conditions
COPD
Seizures
TBI
Urinary Incontinence
Arrhythmias
Depression
Delirium/Confusion
Cancer
Loss of Coordination
PD
Agitation
Asthma
Loss of Appetite
Bradycardia
Eyeglasses
Hearing Aids
Abdominal Cramps
Tachycardia
Pneumonia
Vomiting
Nausea
Diarrhea
Dry Mouth
Clots

% (N)
61.4% (51)
27.7% (23)
4.8% (4)
% (N)
47% (39)
42.2% (35)
3.6% (3)
% (N)
63.9% (53)
53.0% (44)
44.6% (37)
27.7% (23)
26.5% (22)
22.9% (19)
22.9% (19)
19.3% (16)
13.3% (11)
10.8% (9)
8.4% (7)
7.2% (6)
7.2% (6)
6.0% (5)
6.0% (5)
6.0% (5)
6.0% (5)
3.6% (3)
2.4% (2)
2.4% (2)
2.4% (2)
1.2% (1)
1.2% (1)
1.2% (1)
0% (0)
0% (0)
0% (0)
0% (0)
0% (0)
0% (0)
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5.1.2 Functional Outcomes
The use of the FCI enabled important variables to remain in the dataset, including the use of
visual or hearing aids. Otherwise these would have been removed due to less than five values
per disease state. Additionally, the patients who were only at PGH for a month or less were
excluded. Therefore a total of 79 patients were included in the final analyses. There were a total
of 1131 time points included for all 79 patients and none of the patients or time points were
excluded. The minimum number of months was 2 and the maximum number of months for an
individual was 40. Table 14 provides a description of the patients that were removed and why.
Table 14: Patients Excluded from the Analysis

Patient
Number
5
6
15
16
17
31
36
37
38
39
40
41
56
63
64
65
70
71

Dataset Removed From
79 Patients / AR
66 Patients / AR
66 Patients / AR
79 Patients / AR
66 Patients / AR
66 Patients / AR
66 Patients
79 Patients / AR
66 Patients / AR
79 Patients / AR
66 Patients / AR
66 Patients
N/A
66 Patients / AR
66 Patients
66 Patients / AR
66 Patients / AR
66 Patients / AR

Reason for Removal (1 Time Point = 1
Month)
< 2 time points
< 6 time points
< 6 time points
< 2 time points
< 6 time points
< 6 time points
< 6 time points
< 2 time points
< 6 time points
< 2 time points
< 6 time points
< 6 time points
Patient record not found at PGH
< 6 time points
< 6 time points
< 6 time points
< 6 time points
< 6 time points
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5.1.2.1 Autoregressive (AR1) Structure
There were 69 subjects and total of 618 time points for the dataset that was used for a GEE with
an AR1 correlation structure. The relationship between logarithmic FIMS scores and ADS
scores were assessed univariately. As shown below (Table 15), there is not an association
between ADS and FIMS scores.
Table 15: Relationship between FIMS and ADS Scores

Parameter

(Intercept)
ADS

B

2.859
-.019

Std.
Error
.0585
.0111

95% Wald
Confidence Interval
Lower

Upper

2.744
-.041

2.974
.002

Hypothesis Test
Wald
ChiSquare
2384.738
3.026

df

Sig.
1
1

.000
.082

To assess which of the other variables are important predictors the rest of the variables were run
univariately. The following variables were significant, FIMSMonth (time), race, current use of
ChEIs or memantine, residence, history of alcohol use, and FCI score. The parameter estimates
for these variables and ADS score are included in Table 16.
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Table 16: Autoregressive Parameter Estimates
Parameter

(Intercept)
FIMSMonth
[ChEIMemantine=0]
[ChEIMemantine=1]
[ChEIMemantine=2]
[Race=1]
[Race=2]
[Race=3]
[Race=5]
[Alcohol=0]
[Alcohol=1]
[Alcohol=2]
[Alcohol=9]
[Residence=1]
[Residence=2]
[Residence=3]
[Residence=4]
[Residence=9]
ADS
FCI
(Scale)

95% Wald Confidence
Interval
B
3.559
-.015
.252
.205
0a
-.574
-.460
-.220
0a
-.545
-.500
-.450
0a
.415
.556
.048
.229
0a
-.009
.018
.215

Std.
Error
.3781
.0023
.1056
.1178
.
.0825
.1377
.1457
.
.3606
.3425
.3541
.
.1667
.1602
.1676
.0996
.
.0102
.0098

Lower
2.818
-.019
.045
-.026
.
-.735
-.730
-.506
.
-1.252
-1.171
-1.144
.
.089
.242
-.281
.034
.
-.029
-.001
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Upper
4.300
-.010
.459
.436
.
-.412
-.190
.065
.
.161
.171
.244
.
.742
.870
.376
.424
.
.011
.037

Hypothesis Test
Wald ChiSquare
df
Sig.
88.598
1
.000
39.356
1
.000
5.686
1
.017
3.016
1
.082
.
.
.
48.423
1
.000
11.143
1
.001
2.290
1
.130
.
.
.
2.287
1
.130
2.131
1
.144
1.616
1
.204
.
.
.
6.211
1
.013
12.066
1
.001
.082
1
.775
5.282
1
.022
.
.
.
.773
1
.379
3.264
1
.071

Model fit is assessed by the quasi log likelihood under the independence criterion (QIC). The
QIC is similar to the maximum likelihood function used in GEE. The QIC offers a rough guide
of goodness of fit and can be used to compare nested models when choosing the best subset of
predictors (Norusis, 2008). A model with a QIC that is smaller reflects that it is more effective at
predicting than a model with a larger QIC (Norusis, 2008). Models with different predictor
variables cannot be compared to each other using the QIC, only the models with different
correlation structures and the same predictors. In the model displayed in Table 16, the QIC was
250.65. The QICs for the five models is located in Table 25.
5.1.2.2 Exchangeable Structure – 79 Patient Dataset
The second correlation structure evaluated was exchangeable with 79 patients, followed by the 5dependent correlation structure. This 79 patient dataset includes all patients with at least two
time points. Then both structures were run using the dataset with only 66 patients. This dataset
includes only those with at least six time points. The description of the patients who were
excluded and why are located in Table 14.
When the exchangeable results are reviewed, there are 1131 observations included without any
missing data. The relationship between logarithmic FIMS scores and ADS scores were assessed
univariately. As shown below (Table 17), there is not an association between ADS and FIMS
scores.
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Table 17: Exchangeable Structure – Relationship between FIMS and ADS Scores for 79
Patients

Parameter

(Intercept)
ADS

B

2.929
-.030

Std.
Error
.0882
.0234

95% Wald Confidence
Interval
Lower

Upper

2.756
-.076

3.101
.016

Hypothesis Test
Wald
ChiSquare
1102.166
1.676

df

Sig.
1
1

.000
.195

To assess which of the other variables are important predictors the rest of the variables were run
univariately. The following variables were significant, FIMSMonth (time), race, marital status,
length of stay (LOS), and residence. The parameter estimates for these variables and ADS score
are included in Table 18. Marital status and LOS are no longer significant in this total model,
but remain as they were univariately significant with the logarithmic transformation of FIMS
score. Additionally, increased LOS is known to be associated with poorer outcomes.

Table 18: Exchangeable Structure Model for 79 Patients
Parameter

(Intercept)
[Race=1]
[Race=2]
[Race=3]
[Race=4]
[Race=5]
[MaritalStatus=1]

95% Wald
Confidence Interval
B
Std. Error
3.299
.2895
-.411
.2026
-.245
.2083
.200
.2159
.352
.2632
a
0
.
-.232
.2002

Lower
Upper
2.732 3.867
-.808 -.014
-.653
.164
-.224
.623
-.163
.868
.
.
-.624
.160
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Hypothesis Test
Wald ChiSquare
df
Sig.
129.852
1
.000
4.119
1
.042
1.380
1
.240
.854
1
.355
1.793
1
.181
.
.
.
1.343
1
.247

Parameter

95% Wald
Confidence Interval
B

[MaritalStatus=2]
[MaritalStatus=3]
[MaritalStatus=4]
[MaritalStatus=5]
[MaritalStatus=9]
[Residence=1]
[Residence=2]
[Residence=3]
[Residence=4]
[Residence=9]
FIMSMonth
ADS
LOS
(Scale)

Std. Error

Lower

-.076
.2688
-.311
.2066
-.220
.2247
-.457
.2679
a
0
.
.527
.1725
.699
.1488
.044
.1664
.208
.0911
a
0
.
-.014
.0024
-.023
.0178
5.871E-5 6.5490E-5
.224

-.603
-.716
-.660
-.982
.
.189
.407
-.282
.030
.
-.019
-.058
-6.965E-5

Hypothesis Test
Wald ChiUpper
Square
df
Sig.
.451
.094
.221
.069
.
.865
.991
.370
.387
.
-.010
.012
.000

.079
2.272
.958
2.903
.
9.325
22.048
.070
5.224
.
34.970
1.723
.804

1
1
1
1
.
1
1
1
1
.
1
1
1

.778
.132
.328
.088
.
.002
.000
.791
.022
.
.000
.189
.370

5.1.2.3 5-Dependent Structure – 79 Patient Dataset
When the 5-dependent results are reviewed, there are 1131 observations included without any
missing data. The relationship between logarithmic FIMS scores and ADS scores were assessed
univariately. As shown below (Table 19), there is not an association between ADS and FIMS
scores.
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Table 19: 5-Dependent Structure – Relationship between FIMS and ADS Scores for 79
Patients

Parameter

(Intercept)
ADS

B

2.790
.005

Std.
Error
.0628
.0130

95% Wald Confidence
Interval
Lower

Upper

2.667
-.021

2.913
.030

Hypothesis Test
Wald
ChiSquare
1973.088
.122

df

Sig.
1
1

.000
.727

To assess which of the other variables are important predictors the rest of the variables were run
univariately. The following variables were significant, FIMSMonth (time), residence, history of
smoking and alcohol use, race, and length of stay (LOS). The parameter estimates for these
variables and ADS score are included in Table 20. History of smoking and alcohol use, and LOS
are no longer significant in this total model, but remain as they were univariately significant with
the logarithmic transformation of FIMS score. Additionally, history of smoking, and alcohol,
and increased LOS are known to be associated with poorer outcomes.
When the exchangeable and the 5-dependent reduced 2 models are compared the QICs are
489.38 and 451.31, respectively. Based on the goodness of fit, the 5-dependent is a better model
when the 79 patient dataset is used.
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Table 20: 5-Dependent Structure Model for 79 Patients
Parameter

(Intercept)
[Race=1]
[Race=2]
[Race=3]
[Race=4]
[Race=5]
[Residence=1]
[Residence=2]
[Residence=3]
[Residence=4]
[Residence=9]
[Smoking=0]
[Smoking=1]
[Smoking=2]
[Smoking=9]
[Alcohol=0]
[Alcohol=1]
[Alcohol=2]
[Alcohol=9]
FIMSMonth
ADS
LOS
(Scale)

95% Wald
Confidence Interval
B
3.517
-.690
-.524
.029
.211
0a
.515
.559
.086
.224
0a
-.036
.230
.014
0a
-.332
-.385
-.249
0a
-.014
.016
8.434E-5
.208

Std. Error
Lower
.2765
2.975
.0647
-.817
.0989
-.718
.1624
-.290
.1423
-.068
.
.
.1703
.181
.1384
.288
.1616
-.231
.0993
.030
.
.
.2855
-.596
.3112
-.380
.2869
-.548
.
.
.3486
-1.015
.3334
-1.038
.3343
-.904
.
.
.0028
-.020
.0128
-.009
5.9287E-5 -3.186E-5
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Upper
4.059
-.563
-.331
.347
.490
.
.848
.831
.402
.419
.
.523
.840
.576
.
.351
.269
.406
.
-.009
.042
.000

Hypothesis Test
Wald ChiSquare
df
Sig.
161.814
1
.000
113.879
1
.000
28.141
1
.000
.031
1
.861
2.200
1
.138
.
.
.
9.131
1
.003
16.336
1
.000
.281
1
.596
5.104
1
.024
.
.
.
.016
1
.899
.545
1
.461
.002
1
.961
.
.
.
.907
1
.341
1.331
1
.249
.555
1
.456
.
.
.
25.362
1
.000
1.635
1
.201
2.024
1
.155

5.1.2.4 Exchangeable Structure – 66 Patient Dataset
When the exchangeable results for the smaller dataset are reviewed, there are 1087 observations
included without any missing data. The relationship between logarithmic FIMS scores and ADS
scores were assessed univariately. As shown below (Table 21), there is not an association
between ADS and FIMS scores.
Table 21: Exchangeable Structure – Relationship between FIMS and ADS Scores for 66
Patients

Parameter

(Intercept)
ADS

B

2.866
-.031

Std.
Error
.0894
.0235

95% Wald Confidence
Interval
Lower

Upper

2.691
-.077

3.041
.016

Hypothesis Test
Wald
ChiSquare
1027.506
1.691

df

Sig.
1
1

.000
.193

To assess which of the other variables are important predictors the rest of the variables were run
univariately. The following variables were significant, FIMSMonth (time), FCI score, history of
smoking and alcohol use, race, residence, and current use of ChEIs or memantine.

The

parameter estimates for these variables and ADS score are included in Table 22. History of
smoking and use of ChEIs and memantine are no longer significant in this total model, but
remain as they were univariately significant with the logarithmic transformation of FIMS score.
Additionally, history of smoking is known to be associated with poorer outcomes.
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Table 22: Exchangeable Structure Model for 66 Patients

Parameter

95% Wald Confidence
Interval

(Intercept)

B
3.387

Std. Error
.3172

Lower
2.765

Upper
4.009

FCI
[Race=1]
[Race=2]
[Race=3]
[Race=5]
[ChEIMemantine=0]
[ChEIMemantine=1]
[ChEIMemantine=2]
[Smoking=0]
[Smoking=1]
[Smoking=2]
[Smoking=9]
[Residence=1]
[Residence=2]
[Residence=3]
[Residence=4]
[Residence=9]
[Alcohol=0]
[Alcohol=1]
[Alcohol=2]
[Alcohol=9]
ADS
FIMSMonth
(Scale)

.036
-.433
-.335
.243
0a
.014
-.055
0a
.227
.541
.258
0a
.490
.600
.027
.219
0a
-.574
-.684
-.527
0a
-.026
-.014
.221

.0096
.0982
.1547
.1898
.
.1439
.1533
.
.2425
.2657
.2539
.
.2540
.1894
.2507
.1577
.
.2742
.2261
.2599
.
.0183
.0024

.017
-.626
-.638
-.129
.
-.268
-.356
.
-.248
.021
-.239
.
-.008
.229
-.464
-.090
.
-1.111
-1.128
-1.037
.
-.062
-.019

.055
-.241
-.031
.615
.
.296
.245
.
.703
1.062
.756
.
.988
.972
.519
.528
.
-.036
-.241
-.018
.
.010
-.009
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Hypothesis Test
Wald
ChiSquare df Sig.
114.01
1 .000
8
14.096
1 .000
19.474
1 .000
4.681
1 .030
1.640
1 .200
.
.
.
.009
1 .924
.130
1 .719
.
.
.
.878
1 .349
4.152
1 .042
1.035
1 .309
.
.
.
3.723
1 .054
10.038
1 .002
.012
1 .913
1.931
1 .165
.
.
.
4.380
1 .036
9.163
1 .002
4.114
1 .043
.
.
.
2.070
1 .150
35.340
1 .000

5.1.2.5 5-Dependent Structure – 66 Patient Dataset
When the 5-dependent results for the smaller dataset are reviewed, there are 1087 observations
included without any missing data. The relationship between logarithmic FIMS scores and ADS
scores were assessed univariately. As shown below (Table 23), there is not an association
between ADS and FIMS scores.
Table 23: 5-Dependent Structure – Relationship between FIMS and ADS Scores for 66
Patients

Parameter

(Intercept)
ADS

B

2.753
.005

Std.
Error
.0641
.0132

95% Wald Confidence
Interval
Lower

Upper

2.628
-.021

2.879
.031

Hypothesis Test
Wald
ChiSquare
1845.427
.136

df

Sig.
1
1

.000
.712

To assess which of the other variables are important predictors the rest of the variables were run
univariately. The following variables were significant, FIMSMonth (time), FCI score, history of
smoking and alcohol use, race, residence, and current use of ChEIs or memantine. The parameter
estimates for these variables and ADS score are included in Table 24. All of the predictors
except for time and race were no longer significant in the combined model. They were left in as
they had a significant relationship with FIMS score and many are known to be associated with
worsening outcomes in dementia.
When the exchangeable and the 5-dependent reduced 2 models are compared the QIC is 500.14
and 420.58, respectively. Based on the goodness of fit, the 5-dependent is a better model.
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When all five models are compared and their QIC’s are reviewed, Table 25, the autoregressive
correlation structure is the best, with the lowest QIC that is at least half the other models.
Table 24: 5-Dependent Structure Model for 66 Patients

Parameter

(Intercept)
FCI
[ChEIMemantine=0]
[ChEIMemantine=1]
[ChEIMemantine=2]
[Race=1]
[Race=2]
[Race=3]
[Race=5]
[Residence=1]
[Residence=2]
[Residence=3]
[Residence=4]
[Residence=9]
[Smoking=0]
[Smoking=1]
[Smoking=2]
[Smoking=9]
[Alcohol=0]
[Alcohol=1]
[Alcohol=2]
[Alcohol=9]
ADS
FIMSMonth

95% Wald Confidence
Interval
B
3.421
.010
.213
.189
0a
-.634
-.464
-.048
0a
.324
.325
-.106
.090
0a
.270
.399
.317
0a
-.611
-.587
-.505
0a
.020
-.012

Std.
Error
.2984
.0117
.1044
.1124
.
.0825
.1292
.1766
.
.1967
.1667
.1937
.1147
.
.2666
.2782
.2751
.
.2864
.2469
.2727
.
.0136
.0023

Lower
2.837
-.013
.008
-.031
.
-.795
-.717
-.394
.
-.062
-.002
-.486
-.135
.
-.253
-.146
-.222
.
-1.173
-1.071
-1.040
.
-.007
-.017
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Upper
4.006
.033
.418
.410
.
-.472
-.211
.298
.
.709
.652
.273
.315
.
.792
.944
.856
.
-.050
-.103
.029
.
.046
-.008

Hypothesis Test
Wald ChiSquare
df Sig.
131.505 1 .000
.769 1 .380
4.154 1 .042
2.838 1 .092
.
.
.
58.975 1 .000
12.911 1 .000
.074 1 .786
.
.
.
2.709 1 .100
3.802 1 .051
.301 1 .583
.617 1 .432
.
.
.
1.024 1 .312
2.060 1 .151
1.328 1 .249
.
.
.
4.552 1 .033
5.641 1 .018
3.436 1 .064
.
.
.
2.079 1 .149
29.370 1 .000

Table 25: Goodness of Fit for Five Models
Model

Goodness of Fit (QIC)

Autoregressive
Exchangeable (79 patients)
5-Dependent (79 patients)
Exchangeable (66 patients)
5-Dependent (66 patients)

250.65
489.38
451.31
500.14
420.58

5.1.3 Cognitive Outcomes
For the secondary outcome of cognition, the exchangeable and autoregressive structures were
used. Exchangeable structure was run using the dataset with 66 patients as this produced a better
model compared to the one that used all 79 patients. The autoregressive structure was run using
the dataset with 69 patients with time measured quarterly. This was based on the fact that these
are the two most common structures used for binary data (Lee et al, 2007).
When the model was run using the datasets, there was an error obtained relating to convergence.
Therefore, a correlation table for all of the variables and the outcome of cognition was run. This
table displayed a significant correlation of greater than 0.5 for LOS and FIMS Month. As a
result LOS was removed and the analysis was re-run. The same error message relating to the
inability of the model to reach convergence appeared. It was then hypothesized that the model
was over parameterized; therefore each variable was individually run against the outcome of
cognition.
The relationship between cognitive outcomes and ADS scores using the exchangeable and
autoregressive structures are located in Tables 26.
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Table 26: Relationship between Cognition and ADS Scores

Parameter

(Intercept)
ADS

Parameter

B

-.172
-.033

B

Std.
Error

.2196
.0554

Std.
Error

Exchangeable Structure
95% Wald
Confidence Interval
Lower

Upper

-.602
-.142

.259
.076

-.400
.011

.1893
.0428

Wald
ChiSquare
.611
.351

AR1 Structure
95% Wald
Confidence Interval
Lower

(Intercept)
ADS

Hypothesis Test

-.771
-.073

Upper
-.029
.095

df

Sig.

1
1

.435
.553

Hypothesis Test
Wald
ChiSquare
4.469
.070

df

Sig.
1
1

.035
.792

The relationship is shown above and there is not an association between ADS scores and
cognition using either of the two structures. There were other variables that were significant
predictors of change in cognition for the exchangeable structure. These included race, residence,
presence of constipation, and time (FIMS Month). The same procedure was done for the AR1
structure and the significant variables were presence of constipation and time. The parameter
estimates for both structures with only the significant variables are located in Table 27. The
goodness-of-fit tests were evaluated between the two structures.

Again, the autoregressive

structure had a smaller QIC of 1187.83 compared to 1973.33 for the exchangeable structure.

100

The model that predicts the outcome variable of change in cognition is the autoregressive
correlation structure. The effects that were significant and therefore predictive of the outcome
include time and presence of constipation on admission.
Table 27: Cognitive Outcome – AR1 and Exchangeable Structure
Parameter Estimates for Significant Variables for the AR1 Structure
Parameter

95% Wald Confidence
Interval

(Intercept)
[Constipation=1]
[Constipation=0]
FIMSMonth

B
-.132
.927
0a
-.031

Std.
Error
.1966
.2719
.
.0072

Lower
-.517
.394
.
-.045

Upper
.253
1.460
.
-.017

Hypothesis Test
Wald ChiSquare
df
.450
1
11.630
1
.
.
18.905
1

Sig.
.502
.001
.
.000

Parameter Estimates for Significant Variables for Exchangeable Structure
Parameter

(Intercept)
[Race=3]
[Race=2]
[Race=1]
[Race=0]
[Residence=4]
[Residence=3]
[Residence=2]
[Residence=1]
[Residence=0]
[Constipation=1]
[Constipation=0]
LOS

95% Wald Confidence
Interval
B
-1.172
-2.140
-.296
-.366
0a
1.371
.991
1.366
1.361
0a
.962
0a
-.001

Std.
Error
.2693
.2131
.2631
.2583
.
.2543
.2887
.3983
.3721
.
.2865
.
.0002

Lower
-1.700
-2.558
-.812
-.872
.
.872
.425
.585
.632
.
.400
.
-.001
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Upper
-.644
-1.723
.219
.141
.
1.869
1.557
2.146
2.090
.
1.524
.
.000

Hypothesis Test
Wald ChiSquare
df
18.929
1
100.875
1
1.269
1
2.003
1
.
.
29.055
1
11.779
1
11.757
1
13.378
1
.
.
11.274
1
.
.
10.693
1

Sig.
.000
.000
.260
.157
.
.000
.001
.001
.000
.
.001
.
.001

5.1.4 Behavioral Outcomes
The other secondary outcome of behavior was also evaluated using the exchangeable structure
and autoregressive structures. The same warnings associated with cognition emerged when the
model was run with all of the variables. Therefore each variable was run univariately with
behavior and then the significant variables were run together.
The relationship between cognitive outcomes and ADS scores using the exchangeable and
autoregressive structures are located in Tables 28.
Table 28: Relationship between Behavior and ADS Scores

Parameter

B

Std.
Error

Exchangeable Structure
95% Wald
Confidence Interval
Lower

(Intercept)
ADS

Parameter

.853
-.001

B

.1971
.0497

Std.
Error

.467
-.098

.875
.005

.2133
.0538

1.239
.096

AR1 Structure
95% Wald
Confidence Interval
Lower

(Intercept)
ADS

Upper

.457
-.100
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Upper
1.293
.111

Hypothesis Test
Wald
ChiSquare
18.733
.000

df

Sig.
1
1

.000
.983

Hypothesis Test
Wald
ChiSquare
16.820
.010

df

Sig.
1
1

.000
.921

The relationship is shown above and there is not an association between ADS scores and
behavior using either of the two structures. There were other variables that were significant
predictors of change in behavior.

The parameter estimates for the autoregressive and

exchangeable structures are located in Table 29. For the AR structure the following were the
significant variables, time, race, age, presence of constipation, and residence.

For the

exchangeable structure the significant variables were time, race, marital status, smoking and
presence of constipation.
The goodness-of-fit tests were evaluated between the two structures. Again, the autoregressive
structure had a smaller QIC of 1465.44 compared to 2489.34 for the exchangeable structure.
Table 29: Behavioral Outcomes using AR1 and Exchangeable Structure
Parameter Estimates for Significant Variables for AR1 Structures
Parameter

(Intercept)
[Constipation=1]
[Constipation=0]
[Residence=4]
[Residence=3]
[Residence=2]
[Residence=1]
[Residence=0]
[Race=3]
[Race=2]
[Race=1]
[Race=0]
Age
FIMSMonth

95% Wald Confidence
Interval
B
3.914
.683
0a
1.678
1.028
1.560
.987
0a
-2.287
.252
.817
0a
-.055
-.024

Std.
Error
1.6627
.3544
.
.2774
.3365
.5475
.3773
.
.2624
.3312
.2470
.
.0237
.0056

Lower
.655
-.012
.
1.135
.368
.487
.247
.
-2.801
-.398
.333
.
-.102
-.035
103

Upper
7.173
1.377
.
2.222
1.687
2.633
1.726
.
-1.772
.901
1.301
.
-.009
-.013

Hypothesis Test
Wald ChiSquare
df
5.541
1
3.713
1
.
.
36.611
1
9.331
1
8.122
1
6.840
1
.
.
75.932
1
.577
1
10.942
1
.
.
5.396
1
18.331
1

Sig.
.019
.054
.
.000
.002
.004
.009
.
.000
.447
.001
.
.020
.000

Parameter Estimates for Significant Variables for Exchangeable Structure
Parameter
95% Wald Confidence
Interval
Hypothesis Test
Wald ChiB
Std. Error
Lower
Upper
Square
df Sig.
(Intercept)
-3.289
.7094
-4.679
-1.899
21.495 1 .000
[Race=0]
5.212
.4731
4.285
6.139
121.382 1 .000
[Race=1]
2.652
.2170
2.227
3.078
149.384 1 .000
[Race=2]
3.141
.3459
2.463
3.819
82.465 1 .000
a
[Race=3]
0
.
.
.
.
.
.
[MaritalStatus=0]
1.134
.9743
-.776
3.043
1.354 1 .245
[MaritalStatus=1]
1.397
.4206
.573
2.222
11.031 1 .001
[MaritalStatus=2]
.547
.3471
-.133
1.227
2.482 1 .115
[MaritalStatus=3]
.905
.4802
-.036
1.846
3.549 1 .060
[MaritalStatus=4]
1.175
.5513
.094
2.255
4.540 1 .033
a
[MaritalStatus=5]
0
.
.
.
.
.
.
[Smoking=0]
1.006
.3447
.331
1.682
8.526 1 .004
[Smoking=1]
.611
.5177
-.404
1.625
1.392 1 .238
[Smoking=2]
1.489
.4168
.672
2.306
12.761 1 .000
a
[Smoking=3]
0
.
.
.
.
.
.
[Constipation=0]
-.567
.2393
-1.036
-.098
5.615 1 .018
a
[Constipation=1]
0
.
.
.
.
.
.
FIMSMonth
-.024
.0064
-.037
-.012
14.697 1 .000
5.1.5 Summary of Results
In this study there are three outcomes of interest with the use of AC medications. Function, was
the primary outcome of interest and several models using different sized datasets were compared.
By altering the recorded arrangement of time from the first and last consecutive six months with
time measured quarterly between these time periods, to a more uniform time structure made a
difference in determining the model with the best predictive ability. This structure with the best
predictive ability was the AR1 one, based on its QIC value.
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An association between anticholinergic burden, using ADS scores, and function was not found.
The p-values shown in Tables 15-23, demonstrate the burden was not statistically associated with
function. The p-value in Table 15, using the AR1 structure, suggested that burden might have an
effect on function, but when the other significant variables were included in an analysis, the
variable became not significant.
There were other variables that were associated with function using the AR1 structure. These
include, time (FIMSMonth), race, current use of ChEIs or memantine, residence, history of
alcohol use, and FCI score. Higher FIMS scores or improved function was negatively associated
with time (-.02) and White (-.57) or Black (-.46) race. The higher functional scores were
positively associated with the use of memantine or a ChEIs (.21) and living at home (with or
without assistance) prior to admission to PGH (.556 and .415). The other variables were no
longer significant in the combined model. Individually, prior use of alcohol (-.67) had a negative
relationship with higher function.

Additionally, FCI (.03) had a positive association with

increased FIMS scores. The individual associations between these six variables and function
were all highly significant.
The second outcome of interest was cognition, which was a binomial variable. There were two
correlation structures that were used to identify the best model for this outcome. Exchangeable
and autoregressive were the two structures compared.

The results identified that the

autoregressive was the better model
Burden was not associated with cognitive outcomes. The variable was highly insignificant as a
predictor of change in cognition. The variables that were statistically significant as predictors of
change in cognition include the presence of constipation on admission and time. Time (-.03) was
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negatively associated and the presence of constipation (.93) was positively associated with
change in cognition. This is shown in Table 27.
The third outcome of interest was behavior, also a binomial variable.

Two structures,

exchangeable and autoregressive were compared. The autoregressive structure was again the
more robust of the two and produced a better model. In this model, burden was not associated
with change in behavior. There were other variables that were statistically significant with
change in behavior and these include time, race, age, presence of constipation, and residence.
Time was negatively (-.02) associated with change in behavior as was age (-.06) and White race
(-.79). Presence of constipation on admission (.68) and any residence prior to admission was
positively associated with a change in behavior as shown in Table 29.
When all of the variables are considered, time is a predictor of all three outcomes. Additionally,
there other variables predictive of two of the outcomes including race, residence, and presence of
constipation on admission.
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Chapter 6
Discussion and Conclusions

6.1 Discussion
Older adults are at increased risk of developing negative side effects and adverse events from
medications, especially those with AC activity.

This is suggested to be true for older adults

with dementia as well. There is an increasing amount of evidence that consequences including
increased cognitive impairment, physical impairment and rapid functional decline are
associated with drugs that have a high AC burden in patients with dementia (Kowlanski et al,
2009).
Several studies have shown the efficacy of using non-invasive tools to calculate AC burden in
older adults. Carnahan et al developed the Anticholinergic Drug Scale (ADS) that calculates
AC burden based on a rating scale that categorizes medications as “3” known to be highly AC
to “0” no known AC effects (Carnahan et al, 2006). This tool was used in this study to
calculate burden.
This study evaluated the effects of burden on function, cognition, and behavior in moderate to
severe dementia patients in a state run psychiatric hospital. Few studies have investigated the
effects of AC burden on function in moderate to severe AD patients. This is the only study, to
the knowledge of the author, to specifically evaluate these effects in a state run hospitalized
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setting. Furthermore, few studies have evaluated these effects on behavior and cognition as
well in this patient population. This study did not find a statistical association between AC
burden and functional impairment. Additionally, a statistical association was not seen with AC
burden and either cognitive or behavioral outcomes. One possible reason for this outcome
could be specific drugs that are not considered to be highly AC according to the ADS but are
known to cause functional impairment in older adults and dementia patients. Benzodiazepines
and antipsychotics have been shown to be associated with negative outcomes in older adults
and those with dementia (Hilmer et al, 2009), but only a few in each class have AC properties
according to the SAA assays.
6.2 Burden Effects on Function
Much of the evidence of AC burden being associated with poorer outcomes is in older adults
without dementia. This is discussed in section 1.2, where much of the evidence is from studies
in psychiatrically stable older adults. Furthermore, some of the scales used to quantify burden
use older adults without dementia or cognitive impairment. This may be one reason why the
current study failed to show an association between burden and outcomes.

The studies

conducted in cognitively stable and community residing older adults are an important starting
point as much of the inappropriate or AC medication use is not exclusive to this population. It
is also not uncommon in nursing homes and hospitals where there are an increasing number of
moderate to severe dementia patients. In a study by Landi et al, inappropriate medications
including some that have AC properties were associated with impaired physical performance,
muscle strength and functional status (Landi et al, 2007). Inappropriate medications have been
shown to increase the risk of falls (Nebes et al, 2007) and therefore higher morbidity and
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mortality in an already vulnerable population. There are few studies that have investigated the
association between AC burden and function in dementia patients. One such study by Sink et
al, found a decline in higher functioning dementia patients taking AC medications and
functional impairment. The decline in the seven components of the activities of daily living
(ADLs) was 1.62 in patients taking tolterodine and oxybutynin compared 1.08 for those not
taking the two AC medications (Sink et al, 2008). The two medications used in the study are
level 3 AC medications. The most commonly used medications in this study of moderate to
severe dementia patients at PGH, used medications that were levels 1 and 2 medications.
Additionally, while statistical significance was not determined for the association between AC
burden and function, the results are inconclusive based on the limitations of the study and the
limited amount of evidence in the literature.
6.3 Other Effects on Function
In this study, the model found that there are other variables that affect function including time,
race, current use of ChEIs or memantine, residence, history of alcohol use, and FCI score. In
this study impaired function refers to decreased FIMS scores, therefore some of the
relationships between the variables and the outcome are not as expected. Higher FIMS scores
or improved function was negatively associated with time, White or Black race, and use of
alcohol.

As time increased function decreased. Also, decreased functioning was associated

with White or Black races. This may not be an accurate relationship as there were only three
patients who were not classified as White or Black. Lastly, decreased function was associated
with current or previous alcohol use.

Positive associations were found with the use of

memantine or a ChEIs, living at home (with or without assistance) prior to admission to PGH,
and FCI. Higher functioning was associated with patients who used memantine or ChEIs.
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Additionally, those patients that lived at home prior to being admitted to PGH were associated
with higher functional scores. The last association was with FCI, the higher the functioning the
higher number of chronic diseases that affect function. This association is difficult to follow,
as more chronic diseases would be expected to decrease functioning not increase it.
6.4 Effects on Cognition and Behavior
There are numerous studies that have evaluated cognition in those older adults that have
received AC medications.

There are fewer studies in dementia adults compared to non-

demented adults, but the results are the same.

Increased AC burden increases cognitive

impairment, which was described in section 1.2.

This study, however, did not find an

association between burden and worsening cognition. This is counterintuitive especially when
the patients had an average burden score of 3.0. This is a high score compared to a study by
Boustani et al, where the average burden scores were 1.7 using the ACB, a tool similar to the
ADS, in 3013 older adults (Boustani et al, 2008). Another study, by Kowlanski et al, also had a
high burden score of 2.55 in dementia patients and did not find an association between
engagement and burden (Kowlanski et al, 2009). The study by Sink et al also did not find an
association between burden and cognition (Sink et al, 2008). There are several potential
reasons for this including the use of the ADS to quantify burden, the use of subjective measures
of cognition quantified as change or no change, the more severe stress of dementia experienced
by these patients, and possibly the low sample size.

These are described in more detail in

section 6.5.
Behavioral problems typically increase as dementia progresses (1), but few studies have
investigated the increased behavioral problems that are associated with AC medications. The
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studies that discuss behavioral problems in dementia patients, usually do so in the context of
treating them (Edell et al, 2001; Adams et al, 2003).

These studies investigate the use of

antipsychotic medications and their benefits on behavior. Some of these antipsychotics have
AC properties including olanzapine, clozapine, and thioridazine. It would seem that if AC
medications impair function and cognition, then behavior would be impaired as well. In this
study there was not an association between burden and behavior.

The only study that

investigated this relationship did so through engagement (Kowlanski et al, 2009). Where the
dementia participants with increased burden did not have an association with worsening
engagement, specifically, increased sleeping, decreased activity, and increased “doing
nothing.” Future research will need to determine if there is a link between behavior and AC
burden in dementia patients.
6.5 Limitations of Study
The lack of ability to identify an association, if it exists, between function, cognition, and
behavior and AC burden may be explained by several factors related to the design of this study
and the patient population who participated. The first is that all of the participants were at
different stages in their disease when they were admitted to PGH. Severe disease is associated
with greater functional, cognitive, and behavioral deficits that may mask or provide more
influence on these outcomes than AC burden. This was noted in a study by Sink et al that did
not find an association between AC drug use and cognition in more severe dementia patients
(Sink et al, 2008).
A second possibility is the source of the data. Nursing notes in ht medical record are subjective
in assessing cognition and behavior. The inter- and intra-variability among nurses makes it
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inherent that there will be some incorrect interpretations as to the definition of worsening
behavior. In one instance, a patient had been moved from one unit to another due to the
behavioral problems. The notes from the original unit showed worsening behavior, but when
transferred the patient’s behavior stabilized with no major improvement or worsening. Also,
there was not a widely-used definition employed by the investigator (S. Dharia) to determine
change. The use of only one investigator to decipher the notes reduced any bias in the
interpretation of them. Hand-writing, was an additional issue as it made some notes difficult to
interpret.

There are several tools for cognition and behavior in dementia, such as the

Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) (Rosen et al, 1984) or the
Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) (Reisberg et al,
1987), but most are not appropriate in this setting. Several are lengthy and time-consuming or
require the nurse or aide to ask several questions or interview the patient. Tools such as the
Severe Impairment Battery (SIB) may be appropriate in this setting (Albert et al, 1992). Future
research to develop a tool that allows for the nurse or aide to use direct observation to assess
behavior and cognition and takes a short amount of time to fill out would be ideal and reduce
any bias.
There are some limitations of using the ADS. This scale may not fully capture AC burden as it
does not take into account dose. A study that evaluated the relationship between AC burden
and decrease engagement in dementia patients used a similar tool to quantify burden, the
Anticholinergic Burden scale (ACB), did not find an association with burden (Kowlanski et al,
2009).

One limitation that was noted in the study was the limited precision in the

categorization of the AC activity by using the 3-point scale (Kowlanski et al, 2009).
Additionally, the individual differences in absorption, distribution, metabolism and excretion
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are considerable. Using a scale such as the ADS does not take this into account and may
explain the non-statistically significant result. Also, not taking into consideration dose may
affect the outcome. Furthermore, there are several changes in a patient’s medications when an
individual is admitted to PGH in order to stabilize them. Many of the medications used are
antipsychotics that may not be on the ADS scale, even though, these drugs are known to cause
impaired cognition, behavior and function in older adults (Hilmer et al, 2009).

Lastly, there

are several methods for estimating burden, all of which have their strengths and weaknesses,
with no ideal one (Carriere et al, 2009).
Another factor may have been the small number of patients in the study. A larger sample may
provide a significant association. The sample size calculation performed determined that 436
patients were needed in order to obtain 80% power in this study. Increasing the number of
patients would have been difficult in this situation as each of the five state run mental health
hospitals do not use the FIMS as a functional assessment tool. Additionally, not all of the
hospitals have geriatric centered care.
An additional limitation of this study is the observational nature of the research as cause and
effect cannot be established. While there is much speculation as to the strength of evidence
from an observational study, an article found that the average results from randomized,
controlled studies overestimated the magnitude of the associations and the well-designed
observational ones did not (Concato et al, 2000).

Furthermore, the observational studies

evaluated, had less variability in the estimates than did the RCTs on the same cardiovascular
topic. Therefore, the observational design might not be a true limitation of the study.

113

Much of the dementia research concerning the use of medications with AC properties is
performed in AD patients specifically. In this study the original design was to include only AD
patients, but due to the low number all dementia patients were included. AD patients appear to
be at greater risk of negative effects using AC medications due to the etiology of the disease
and the large proportion of this form of dementia compared to the others.

Yet all dementia

patients are vulnerable due the significant cognitive impairment associated with the disease.
6.6 Strengths
Some of the strengths of this study include the data source. The use of medical charts provides
much more information about a participant’s health, medical, and pharmacy data compared to a
claims database. Pharmacy or hospital claims data are sometimes used as an information
source for studies. In the preliminary research study, section 3.1, the first study described used
a procedure and diagnosis specific database that while large in size did not include all of the
pertinent information.
Additionally, the longitudinal nature of the research is an advantage. Compared to a crosssectional method, this method allows for evaluation of an outcome over time and for a truer
representation of the relationship between various effects and the outcomes. It also allows for
stronger associations to be made between outcomes of interest and specific variables.
The use of only one student to collect all of the data, except one patient, minimizes any interrater variability that may have occurred. In addition, when interpreting the subjective nursing
notes, using only one rater minimized any bias.
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Lastly, moderate to severe dementia patients are not widely studied, especially those in staterun psychiatric hospitals.

This study provided knowledge on an underrepresented and

exceedingly vulnerable population due to their disease and special care.
6.7 Future Directions
The majority of the research in the area of AC burden is conducted in older adults that do not
suffer from dementia. What little literature there is on dementia and AC burden is mostly in the
form of case studies or observational studies.
outcomes.

Additionally, many are focused on cognitive

Future research should make use of experimental designs, specifically an

interventional study or make use of national disease databases. This interventional study
should assess the change or improvement in functional, cognitive, and behavioral impairment
caused by AC medications as dementia patients are removed from potentially inappropriate
medications. Furthermore, different levels of burden should be included, to determine if lower
burden causes less harm than more burden.

The intervention should be to remove the

participants from the AC medications and compare them to those who are still currently taking
the medications over a period of time. Outcomes should include at least behavior, function,
and cognition.

A randomized clinical trial (RCT) will provide added evidence as to the

negative effects or no effects of AC burden on dementia patients.

Moreover, an RCT will

provide a better estimate of the potential causal relationship between AC burden and outcomes.
Additionally, the use of a large disease database will have to wait until they have been
completed as they are still in the process of being developed. One potential problem with this
proposed study is the recruitment of patients.

As mentioned in sections 1.4 and 3.2,

recruitment of older adults and those with dementia is a barrier to conducting research
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including experimental and prospective observational studies.

Overcoming this barrier is

imperative to further research in the area of dementia.
6.8 Conclusions
The effect of AC medications on moderate to severe dementia patients is not fully understood.
The minimal amount of literature on this association, suggests that AC burden may have
negative consequences on function, cognition and behavior in dementia patients. This study
provided inconclusive evidence to this current theory that AC burden negatively impacts
function, cognition, and behavior in dementia patients.
overcoming recruitment barriers is essential.
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To further this area of research,
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Appendix A: Patient Intake Form
Subject #: ________
Cognitive, Functional and Behavioral Outcomes Associated with Anticholinergic Drug
use in Alzheimer's disease Patients Taking Cholinesterase Inhibitors
Participant Demographic Form: Please answer the following questions concerning the patient
to the best of your ability. If you have concerns about any of the questions please let us know
at the first visit.
1. Date of Birth (MM/DD/YYYY): ________________
2. Age (in years): ___________
3. Sex (check one):
___Male
___Female
4. Marital Status (check one):
___Married
___Single
___Divorce
___Other
5. Ethnicity (check one):
___White
___Black
___Hispanic
___Asian/Pacific Islander
___American Indian/Alaskan Native
___Other/Not Specified
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6. Residence (check one):
___Home
___Assisted Living Facility
___Other

7. How long have you lived at your current residence:
______________________________
8. Primary care doctor: _________________________________________
9. Have you ever participated in a study or clinical trial (check one):
___Yes
___No
10. Highest Grade Achieved (check one):
___Elementary School
___Middle School
___High School
___College
___Graduate
11. Current Smoker (check one):
___Yes
___No
If yes, how many years: ____
In addition, how many cigarettes per day: ____
12. If no, did you smoke previously (check one):
___Yes
___No
If yes, how long ago: ____
In addition, how many cigarettes per day: ____
13. Current Diagnoses (check as many as apply):
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___Parkinson’s Disease

___Diabetes

___Urinary Incontinence

___Thyroid Problems

___Abdominal Cramps

___Clots

___Diarrhea

___Depression

___Wear Eyeglasses

___Alcohol Problems

___Use Hearing Aids

___Seizures

___Vomiting

___Arthritis

___Nausea

___Cancer

___Loss of Appetite

___High Blood Pressure

___Increase Heart Rate

___Confusion

___High Cholesterol

___Head Trauma

___Heart Murmur

___Loss of Coordination

___Arrhythmias

___Dry Mouth

___Asthma

___Constipation

___Pneumonia

___Agitation

14. Do you have a family history of the following disorders or illnesses:
___Parkinson’s Disease
___Alzheimer’s Disease
___High Cholesterol

___Thyroid Problems

___Diabetes

___Anemia

___Cancer

___Arrhythmias

___High Blood Pressure

___Heart Murmur

15. When were you diagnosed with AD (MM/DD/YYYY): __________________
16. Which medication for AD are you currently taking (check all that apply):
___Aricept
___Exelon
___Razadyne
___Namenda
17. How long have you been taking the above medication (years): ______
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18. Were you previously on a different medication for AD (check one):
___Yes
___No
19. If yes, which one (check all that apply):
___Aricept
___Exelon
___Razadyne
___Namenda
20. Do you think your current AD medication is working (check one):
___Yes
___No
21. Please list all current medications (please back of this page if you run out of space):
Name

Indication

Route

Dosage

How often taken

____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
______________________
22. Please list all current Supplements/Vitamins/Herbals/OTC (please back of this page if
you run out of space):
Name

Indication

Route

Dosage

How taken

_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
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_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
___________________
23. Do you think these medications are working (check one):
___Yes
___No
24. If not, please list which ones are not working:
__________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
______
25. Approximately how much is your annual out of pocket expenditure on medications and
supplements : ________
26. What type of prescription drug insurance do you have (check all that apply):
___Medicare part D
___Medicaid
___Both
___Other
If other, please indicate:
____________________________________________________
27. On how many days per week do you eat red meat: _____
28. What kind of physical exercise do you do (check all that apply):
___Aerobics
___Weight-lifting
___Walking
___Running/Jogging
___Cycling
___Swimming
___Other
If other, please indicate:
____________________________________________________
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29. What kinds of activities do you enjoy (examples - memory games, gardening,
crossword puzzles): ________________________________________________
_________________________________________________________________________
_________________________________________________________________________
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Appendix B: Anticholinergic Drug Scale
Level 3 Drugs
Amitriptyline, dicyclomine, oxybutynin, atropine, dimenhydrinate, procyclidine, benztropine,
diphenhydramine, promethazine, brompheniramine, doxepin, propantheline, carbinoxamine,
flavoxate, protriptyline, chlorpheniramine, hydroxyzine, pyrilamine, chlorpromazine,
hyoscyamine, scopolamine, clemastine, imipramine, thioridazine, clomipramine, meclizine,
tolterodine, clozapine, nortriptyline, trihexyphenidyl, darifenacin, orphenadrine, trimipramine,
desipramine
Level 2 Drugs
Carbamazepine, disopyramide, molindone, cimetidine, loxapine, oxcarbazepine,
cyclobenzaprine, meperidine, pimozide, cyproheptadine, methotrimeprazine, ranitidine
Level 1 Drugs
Alprazolam, divalproex sodium, olanzapine, amantadine, estazolam, oxazepam, ampicillin,
famotidine, oxycodone, azathioprine, fentanyl, pancuronium, bromocriptine, fluoxetine,
paroxetine, captopril, fluphenazine, perphenazine, cefamandole, flurazepam, phenelzine,
cefoxitin, fluticasone-salmeterol, piperacillin, cephalothin, fluvoxamine, prednisolone,
chlordiazepoxide, furosemide, prednisone, chlorthalidone, gentamicin, prochlorperazine,
clindamycin, hydralazine, sertraline, clonazepam, hydrocortisone, temazepam, clorazepate,
isosorbide, theophylline, codeine, isosorbide dinitrate, thiothixene, cortisone, isosorbide
mononitrate, tramadol, cycloserine, ketotifen, ophthalmic triamcinolone, cyclosporine,
loperamide, triamterene, dexamethasone, lorazepam, triazolam, diazepam, methylprednisolone,
trifluoperazine, digitoxin, midazolam, valproic acid, digoxin, morphine, vancomycin, diltiazem,
nifedipine, warfarin, dipyridamole, nizatidine,
Level 0 Drugs
Acarbose, acetaminophen, acetaminophen/dichloralphenazone/isometheptene, acetazolamide,
acetic acid topical, acyclovir, adenosine, albuterol, alendronate, allopurinol, aluminum
carbonate, aluminum hydroxide, amiloride, amiodarone, amlodipine, ammonium lactate
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topical, amoxicillin, amoxicillin-clavulanate, anagrelide, anastrozole, anileridine, apraclonidine
ophthalmic, ascorbic acid, aspirin, atenolol, atorvastatin, azithromycin, bacitracin ophthalmic,
bacitracin topical, baclofen, balsam Peru topical, beclomethasone, beclomethasone nasal,
benazepril, benzocaine topical, benzonatate, beta-carotene, betamethasone topical,
betamethasone-clotrimazole topical, betaxolol ophthalmic, bethanechol, bicalutamide,
bisacodyl, bismuth subsalicylate, bisoprolol, brimonidine ophthalmic, brinzolamide
ophthalmic, budesonide, budesonide nasal, bumetanide, bupropion, buspirone, butabarbital,
butalbital, caffeine, calamine topical, calcipotriene topical, calcitonin, calcitriol, calcium
acetate, calcium and vitamin D, calcium carbonate, camphor-menthol topical, candesartan,
carbachol ophthalmic,
carbamide peroxide otic, carbidopa, carisoprodol, carvedilol, casanthranol,
casanthranoldocusate, cascara sagrada, castor oil, cefaclor, cefazolin, cefixime, ceftibuten,
ceftriaxone, cefuroxime, elecoxib, cephalexin, cerivastatin, cetirizine, cetylpyridinium topical,
chloral hydrate, chlorambucil, chlorhexidine topical, chlorothiazide, chlorpropamide,
chlorzoxazone, cholestyramine, chondroitin, ciclopirox topical, cilastatin, cilostazol,
ciprofloxacin, cisapride, citalopram, clarithromycin, clavulanate, clindamycin topical,
clobazam, clodronate, clonidine, clopidogrel, clotrimazole, cloxacillin, colchicines, colestipol,
collagenase topical, conjugated estrogens, cranberry, cromolyn, cyanocobalamin,
cyclophosphamide, danazol, dantrolene, demeclocycline, desmopressin, desonide topical,
desoximetasone topical, dexamethasone nasal, dexamethasone ophthalmic, dexamethasone
topical, dextromethorphan, diclofenac, dienestrol topical, diflunisal, dihydroxyaluminum
sodium carbonate, diphenoxylate, dipivefrin ophthalmic, dirithromycin, dobutamine, docusate,
donepezil, dopamine, dorzolamide ophthalmic, doxazosin, doxycycline, duloxetine, econazole
topical, edrophonium, enalapril, enoxaparin, entacapone, epoetin alfa, ergocalciferol, ergoloid
mesylates, erythromycin, escitalopram, esomeprazole, esterified estrogens, estradiol, estradiol
topical, estropipate, ethambutol, ethinyl estradiol, etidronate, etodolac, felbamate, felodipine,
fenofibrate, ferrous gluconate, ferrous sulfate, fexofenadine, filgrastim, finasteride, flecainide,
fluconazole, fludrocortisone, flumazenil, flunisolide, fluocinonide topical, fluoride topical,
fluorometholone ophthalmic, flutamide, fluticasone, fluvastatin, folic acid, fosinopril,
gabapentin, galantamine, gemfibrozil, gentamicin ophthalmic, gentamicin topical, ginkgo,
glimepiride, glipizide, glucagons, glucosamine, glyburide, glycerin topical, guaifenesin,
guanfacine, halcinonide topical, haloperidol, heparin, hydrochlorothiazide, hydrocodone,
hydrocortisone ophthalmic, hydrocortisone otic, hydrocortisone topical, hydromorphone,
hydroxychloroquine, hydroxypropyl, methylcellulose ophthalmic, hydroxyurea, ibuprofen,
imipenem, indapamide, indomethacin, insulin, ipratropium, irbesartan, iron polysaccharide,
isoniazid, isradipine, ketoconazole topical, ketoprofen, labetalol, lactase, lactulose, lamotrigine,
lanolin-mineral oil topical, lansoprazole, latanoprost ophthalmic, leuprolide, levobunolol
ophthalmic, levodopa, levofloxacin, levothyroxine, lidocaine, lindane topical, liothyronine,
lisinopril, lithium, loratadine, losartan, loteprednol ophthalmic, lovastatin, LVP solution,
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Lysine, Magnesium preparations, mannitol, medroxyprogesterone, megestrol, meprobamate,
mesalamine, metaxalone, metformin, methazolamide, methenamine, methotrexate,
methyclothiazide, methylcellulose, methyldopa, methylene blue, methylphenidate,
methylprednisolone topical, methyltestosterone, metoclopramide, metolazone, metoprolol,
metronidazole, mexiletine, miconazole topical, midodrine, mineral oil, minocycline,
mirtazapine, misoprostol, moexipril, mometasone nasal, montelukast, moxifloxacin,
multivitamin, mupirocin topical, nabumetone, nadolol, naloxone, naproxen, nateglinide,
nefazodone, neomycin ophthalmic, niacin, nisoldipine, nitrofurantoin, nitroglycerin,
norepinephrine, norfloxacin, nystatin, octreotide, ofloxacin, olopatadine ophthalmic,
omeprazole, oxymetazoline nasal, pamidronate, pancrelipase, pantoprazole, papaverine,
penicillin, pentoxifylline, pergolide, perindopril, permethrin topical, petrolatum topical,
phenazopyridine, Phenobarbital, phenyl salicylate, phenylephrine, phenylpropanolamine,
phenytoin, phytonadione, pilocarpine ophthalmic, pindolol, pioglitazone, pirbuterol, piroxicam,
pivampicillin, polycarbophil, polyethylene glycol electrolyte solution, polymyxin B
ophthalmic, potassium bicarbonate, potassium chloride, potassium citrate, pramipexole,
pramoxine topical, pravastatin, prazosin, prednisolone ophthalmic, primidone, probenecid,
procainamide, progesterone, propafenone, propoxyphene, propranolol, propylthiouracil,
pseudoephedrine, psyllium, pyrazinamide, pyridostigmine, quetiapine, quinapril, quinidine,
quinine, rabeprazole, raloxifene, ramipril, repaglinide, reserpine, rifampin, rimantadine,
rimexolone ophthalmic, risedronate, risperidone, rofecoxib, ropinirole, rosiglitazone, salicylic
acid topical, salmeterol, salsalate, selegiline, selenium sulfide topical, senna, silver sulfadiazine
topical, simethicone, simvastatin, sodium bicarbonate, sodium chloride, sodium phosphate,
sodium sulfacetamide ophthalmic, sotalol, spironolactone, succinylcholine, sucralfate,
sulfamethizole, sulfamethoxazole, sulindac, tacrine, tamoxifen, tamsulosin, terazosin,
terbinafine topical, terbutaline, terconazole topical, tetracycline, thiamine, thyroid desiccated,
ticlopidine, timolol, tobramycin ophthalmic, tolbutamide, tolcapone, topiramate, torsemide,
trandolapril, trazodone, triamcinolone nasal, triamcinolone topical, trichlormethiazide,
triethanolamine, polypeptide, oleate otic, trimethoprim, troglitazone, trypsin, tuberculin
purified protein derivative, ursodiol, valsartan, vecuronium, venlafaxine, verapamil, vitamin E,
zafirlukast, zaleplon, zinc gluconate, zinc sulfate, zolpidem, zopiclone
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Appendix C: PGH Letter of Consent
March 31, 2010
[Mr/Mrs. Patient/AR]
[Street Address]
[City, State ZIP]
RE:

[Patient name/Reg. No.]

Dear [Mr./Mrs. Patient/AR]:
Piedmont Geriatric Hospital has been contacted by a Virginia Commonwealth University (VCU)
graduate student, Sheetal Dharia, who is working toward her doctorate in Pharmacy. She is interested
in using our data for a research project designed to evaluate the possible effects of the use of a
combination of medications that are for health conditions other than Alzheimer’s disease or dementia
on the functional and cognitive status of people who have dementia.
The goals of this project are:
1) To better understand what happens when people with dementia take multiple medications
2) To improve how medications are used in the future for patients with dementia
The student is requesting access to medical and prescription information from the records of the
above named patient. Any identifiable information such as name, date of birth, admission and
discharge dates will not be collected or published for this project. We are notifying you in advance in
order to give you an opportunity to agree or object to the record being accessed for this purpose.
Enclosed you will find a list of the information that will be collected, and an authorization form to sign
if you wish to grant permission for this project. If, however, you object to participation in this research
project, please simply write “I object” at the top of the form and leave the form unsigned. Please
return the form in the enclosed envelope by April 15, 2010. If we have not received a response by
April 19, 2010, we will interpret the lack of response to mean there is no objection. If you have
concerns that you would like to discuss regarding this project, please contact me at (434)767-4411.
Sincerely,
Peggy S. Vaughan
Health Information Manager
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AUTHORIZATION FOR USE/DISCLOSURE/EXCHANGE OF PROTECTED HEALTH INFORMATION

Research Information Sheet

Focus of
Research:

Evaluate possible effects of the combination of medications that are for health conditions
other than Alzheimer’s disease or dementia on the functional and cognitive status of
people with dementia

Information
Collecting:

 Medications
 Scores for thinking and functioning (Nursing documentation)
 Sex
 Marital Status
 Age
 Race/Ethnicity
 Length of Stay at Piedmont Geriatric Hospital
 Number of hospitalizations at Piedmont Geriatric Hospital
 Education (highest grade completed)
 Smoking (No/Yes), if yes-how many cigarettes each day? How many years?
 Drinking (No/Yes), if yes-how much alcohol each day? How many years?
 When dementia was diagnosed
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DBHDS Facility Name:
Telephone Number

Piedmont Geriatric Hospital

: 434-767-4401

Fax: 434-767-4404

Patient Name (Last, First, MI):
DOB:

SS# (optional)

Extent or nature of use/disclosure is limited to: (Check √ or list all that apply)
Discharge Summary

History & Physical

Social Work Assessment

Psychiatric Evaluation

Progress Notes

Physician Orders

Lab Work

Consultations

Treatment Plan

HIV/AIDS Information

Substance Abuse Information

Psychological Evaluation

Other: Medications, Functional scores, sex, marital status, age, race/ethnicity, length of stay, number of hospitalizations at
PGH, education, information regarding smoking/drinking, when dementia was diagnosed
Specified purpose or need for use/disclosure is:
Diagnosis/Treatment
project for a pharmacy graduate student to acquire a doctorate degree.

Permission is hereby given to:

Piedmont Geriatric Hospital

Facility Name & Name of Responsible
Person e.g. (“Facility director or his
authorized designee”)

5001 East Patrick Henry Highway

Discharge Planning

Other, Specify Research

Burkeville, VA 23922

To disclose information to OR

Sheetal Dharia /Patricia Slattum, PharmD, PhD/ VCU School of Pharmacy

To exchange information with:

Department of Pharmacotherapy and Outcome Science

Name, or other specific identification
and organization

th

410 North 12 Street / P. O. Box 980581
Richmond, VA 23298-0581

Street Address, City, State, Zip
Phone/Fax #

Phone: (804)828-6355

Fax: (804)828-1815

I also authorize the recipient to use the information received pursuant to this authorization.
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As the person signing this authorization, I acknowledge that I am giving my permission to the above-named person/class of
persons to disclose and use protected health information. I further acknowledge that:
•
•
•
•

•

I may refuse to sign this authorization.
DBHDS/ Piedmont Geriatric Hospital cannot condition the provision of treatment to me on my signing of this authorization.
The original or a copy of this authorization shall be included with my original records.
I have the right to revoke this authorization at any time, except to the extent that action has been taken in reliance on it, by
delivering the revocation in writing to the provider who is in possession of my health care records.
There is a potential for any information disclosed pursuant to this authorization to be subject to re-disclosure by the recipient and,
therefore, no longer protected by the provisions of the HIPAA Privacy Rule. If this information is being disclosed from records
protected by the Federal substance abuse confidentiality rules (42 CFR part 2), the Federal rules prohibit the recipient from making
any further disclosure of this information unless further disclosure is expressly permitted by your written authorization or as
otherwise permitted by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for
this purpose. The Federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse
patient.

If not previously revoked, this authorization will expire in:
The information may be disclosed effective:
This authorization

does

90 Days

Immediately

One Year

Upon project completion

(specify date)

does not extend to information placed in my record after the date I signed this form.

Signature of Individual (adult) or Legally Authorized Representative

Relationship

Date Signed

Signature of Minor (if required by law)

Date Signed

Witness (optional)

Date Signed
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Appendix D: PGH Collection Form
Subject Number:
Subject Collection Form
Age

Sex: M=0; F=1

Marital Status
Married=1
Single=2
Widowed=3
Divorced=4
Separated=5
Unknown=9

Smoker
How long (years)?

Yes

No

Previous

< K-5
9-12

K-5
> 12+

6-8
Other:

How Many
Cigarettes/Day?
Alcohol
How many drinks per
day?
How long (years)?
Highest Grade
Achieved (Check 1)

Date of Diagnosis
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Ethnicity/Race:
White=1;
Black=2;
Hispanic=3;
Asian/Pacific Islander=4;
American Indian=5;
Unknown=9

Residence (prior to
admission):
Home (No
Assistance)=1;
Home(w/Assistance)=2;
ALF=3;
SNF=4;
Unknown=9

Length of Stay

# of Admissions

Alzheimer's Treatment:
Aricept=1;
Exelon=2;
Razadyne=3;
Namenda=4
Unknown=9

Dose per day:
Yes ___
No ___
Previous
___

Admission conditions:
Absent=0;
Present=1;
Unknown=9

HTN

Constipation

Seizures

Bradycardia

Abdominal
Cramps

Loss of
Coordination
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Tachycardia

Vomiting

Confusion/
Delirium

Arrhythmias

Urinary
Incontinence

Depression

Other CV
Asthma

Nausea
Loss of Appetite

Agitation
TBI

Pneumonia
COPD
Cancer
Wear Eyeglasses
Use Hearing Aids

Diarrhea
Dry Mouth
High Cholesterol
Diabetes
Thyroid Problems

Date

FIMS
Score

Cognitve
Problems
Yes=1; No=2

Parkinson's
Disease
Clots (Any)
Other:

Behavioral Problems
Yes=1; No=2
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ADS Score

Vita

Sheetal Prabodh Dharia was born on February 22, 1981, in Dunedin, Florida, and is an
American citizen. She graduated from the International Baccalaureate program at Palm
Harbor University High School, Palm Harbor, Florida in 1999. She received her
Bachelor’s of Science in Biology with a minor in General Business from the University
of South Florida, Tampa, Florida in 2002 and subsequently worked for a biotechnology
company, Digene Corporation, in Gaithersburg, Maryland for two years. Additionally
she worked for CVS pharmacy for five years as a pharmacy intern. She received a
Doctor of Pharmacy degree and a Certificate in Aging Studies from Virginia
Commonwealth University in May of 2010.
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